US11154597B2 - Sequence arrangements and sequences for neoepitope presentation - Google Patents
Sequence arrangements and sequences for neoepitope presentation Download PDFInfo
- Publication number
- US11154597B2 US11154597B2 US15/468,046 US201715468046A US11154597B2 US 11154597 B2 US11154597 B2 US 11154597B2 US 201715468046 A US201715468046 A US 201715468046A US 11154597 B2 US11154597 B2 US 11154597B2
- Authority
- US
- United States
- Prior art keywords
- sequence
- neoepitope
- polytope
- neoepitopes
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 110
- 238000000034 method Methods 0.000 claims abstract description 80
- 230000032258 transport Effects 0.000 claims abstract description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 65
- 150000007523 nucleic acids Chemical group 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 210000001163 endosome Anatomy 0.000 claims description 31
- 108020004707 nucleic acids Proteins 0.000 claims description 29
- 102000039446 nucleic acids Human genes 0.000 claims description 29
- 230000028993 immune response Effects 0.000 claims description 27
- 230000027455 binding Effects 0.000 claims description 21
- -1 CD86 Proteins 0.000 claims description 19
- 238000004064 recycling Methods 0.000 claims description 18
- 210000003712 lysosome Anatomy 0.000 claims description 16
- 230000001868 lysosomic effect Effects 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 13
- 102000003812 Interleukin-15 Human genes 0.000 claims description 12
- 108090000172 Interleukin-15 Proteins 0.000 claims description 12
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims description 10
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 10
- 241000701161 unidentified adenovirus Species 0.000 claims description 8
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 7
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 7
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 7
- 101150013553 CD40 gene Proteins 0.000 claims description 6
- 102100032937 CD40 ligand Human genes 0.000 claims description 6
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 102000000588 Interleukin-2 Human genes 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 6
- 230000002483 superagonistic effect Effects 0.000 claims description 6
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 5
- 108010057840 ALT-803 Proteins 0.000 claims description 5
- 102100038078 CD276 antigen Human genes 0.000 claims description 5
- 101710185679 CD276 antigen Proteins 0.000 claims description 5
- 108010029697 CD40 Ligand Proteins 0.000 claims description 5
- 102100036008 CD48 antigen Human genes 0.000 claims description 5
- 102100025221 CD70 antigen Human genes 0.000 claims description 5
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 5
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 5
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 5
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 5
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 5
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 claims description 5
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 5
- 102100034980 ICOS ligand Human genes 0.000 claims description 5
- 102000013462 Interleukin-12 Human genes 0.000 claims description 5
- 108010065805 Interleukin-12 Proteins 0.000 claims description 5
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 claims description 5
- 108010042215 OX40 Ligand Proteins 0.000 claims description 5
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 claims description 5
- 101710174757 T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 claims description 5
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 5
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims description 5
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims description 5
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims description 5
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 5
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 5
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 5
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 5
- 108010074108 interleukin-21 Proteins 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- WCZDQPXNBJTKPI-UHFFFAOYSA-O Cyanidin 7-glucoside Chemical compound OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C(C=C(O)C(=[O+]2)C=3C=C(O)C(O)=CC=3)C2=C1 WCZDQPXNBJTKPI-UHFFFAOYSA-O 0.000 claims description 4
- 101000953492 Homo sapiens Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1 Proteins 0.000 claims description 4
- 101150113776 LMP1 gene Proteins 0.000 claims description 4
- 102100023727 Mitochondrial antiviral-signaling protein Human genes 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 3
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 59
- 238000012545 processing Methods 0.000 abstract description 31
- 239000003814 drug Substances 0.000 abstract description 21
- 230000003612 virological effect Effects 0.000 abstract description 18
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 60
- 150000001413 amino acids Chemical group 0.000 description 57
- 108090000765 processed proteins & peptides Proteins 0.000 description 46
- 108700028369 Alleles Proteins 0.000 description 40
- 230000008685 targeting Effects 0.000 description 40
- 241000700605 Viruses Species 0.000 description 39
- 238000004458 analytical method Methods 0.000 description 32
- 230000002132 lysosomal effect Effects 0.000 description 32
- 108010076504 Protein Sorting Signals Proteins 0.000 description 29
- 210000004602 germ cell Anatomy 0.000 description 29
- 102000004196 processed proteins & peptides Human genes 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 28
- 201000011510 cancer Diseases 0.000 description 23
- 230000035772 mutation Effects 0.000 description 23
- 102000004127 Cytokines Human genes 0.000 description 21
- 108090000695 Cytokines Proteins 0.000 description 21
- 210000000805 cytoplasm Anatomy 0.000 description 21
- 102000035195 Peptidases Human genes 0.000 description 16
- 108091005804 Peptidases Proteins 0.000 description 16
- 239000004365 Protease Substances 0.000 description 16
- 108090000848 Ubiquitin Proteins 0.000 description 16
- 102000044159 Ubiquitin Human genes 0.000 description 16
- 230000030741 antigen processing and presentation Effects 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 14
- 238000012163 sequencing technique Methods 0.000 description 14
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 13
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 238000009169 immunotherapy Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 230000002209 hydrophobic effect Effects 0.000 description 11
- 230000005746 immune checkpoint blockade Effects 0.000 description 11
- 210000000822 natural killer cell Anatomy 0.000 description 11
- 230000001086 cytosolic effect Effects 0.000 description 10
- 238000000126 in silico method Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 210000004896 polypeptide structure Anatomy 0.000 description 9
- 230000004936 stimulating effect Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 210000000612 antigen-presenting cell Anatomy 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 102100024263 CD160 antigen Human genes 0.000 description 7
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 7
- 238000003559 RNA-seq method Methods 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 210000000172 cytosol Anatomy 0.000 description 7
- 210000001723 extracellular space Anatomy 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000000392 somatic effect Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical group OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 102000054765 polymorphisms of proteins Human genes 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 102100022339 Integrin alpha-L Human genes 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000005220 cytoplasmic tail Anatomy 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 4
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 4
- 108010075704 HLA-A Antigens Proteins 0.000 description 4
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 4
- 102000004473 OX40 Ligand Human genes 0.000 description 4
- 108010085186 Peroxisomal Targeting Signals Proteins 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000013528 artificial neural network Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 3
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 102100025323 Integrin alpha-1 Human genes 0.000 description 3
- 102100032816 Integrin alpha-6 Human genes 0.000 description 3
- 102100025390 Integrin beta-2 Human genes 0.000 description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
- 210000004322 M2 macrophage Anatomy 0.000 description 3
- 108091092878 Microsatellite Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102100029197 SLAM family member 6 Human genes 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000002552 multiple reaction monitoring Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000037432 silent mutation Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 230000001360 synchronised effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 102100031517 Fc receptor-like protein 1 Human genes 0.000 description 2
- 101150051800 Fcrl1 gene Proteins 0.000 description 2
- 101150032412 Fcrla gene Proteins 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 description 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 2
- 101000848199 Homo sapiens Protocadherin Fat 4 Proteins 0.000 description 2
- 101000709473 Homo sapiens Sialic acid-binding Ig-like lectin 14 Proteins 0.000 description 2
- 101000868472 Homo sapiens Sialoadhesin Proteins 0.000 description 2
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 description 2
- 102100032818 Integrin alpha-4 Human genes 0.000 description 2
- 102100039904 Integrin alpha-D Human genes 0.000 description 2
- 102100022341 Integrin alpha-E Human genes 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 102100034547 Protocadherin Fat 4 Human genes 0.000 description 2
- 102000005917 R-SNARE Proteins Human genes 0.000 description 2
- 108010005730 R-SNARE Proteins Proteins 0.000 description 2
- 102000016681 SLC4A Proteins Human genes 0.000 description 2
- 108091006267 SLC4A11 Proteins 0.000 description 2
- 102100027744 Semaphorin-4D Human genes 0.000 description 2
- 102100034370 Sialic acid-binding Ig-like lectin 14 Human genes 0.000 description 2
- 102100032855 Sialoadhesin Human genes 0.000 description 2
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 description 2
- 101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000010205 computational analysis Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 102200108188 rs587782423 Human genes 0.000 description 2
- 102220098491 rs878853137 Human genes 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 101000716807 Arabidopsis thaliana Protein SCO1 homolog 1, mitochondrial Proteins 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108010056102 CD100 antigen Proteins 0.000 description 1
- 108010017009 CD11b Antigen Proteins 0.000 description 1
- 102100038077 CD226 antigen Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 101710139831 CD82 antigen Proteins 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 102000004172 Cathepsin L Human genes 0.000 description 1
- 108090000613 Cathepsin S Proteins 0.000 description 1
- 102100035654 Cathepsin S Human genes 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100239628 Danio rerio myca gene Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102100036254 E3 SUMO-protein ligase PIAS2 Human genes 0.000 description 1
- 101710201734 E3 protein Proteins 0.000 description 1
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 description 1
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 1
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 1
- 101000893526 Homo sapiens Leucine-rich repeat transmembrane protein FLRT2 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000984192 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101001076715 Homo sapiens RNA-binding protein 39 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 101710123134 Ice-binding protein Proteins 0.000 description 1
- 101710082837 Ice-structuring protein Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 1
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100040899 Leucine-rich repeat transmembrane protein FLRT2 Human genes 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100025582 Leukocyte immunoglobulin-like receptor subfamily B member 3 Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 101100236305 Mus musculus Ly9 gene Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 102000005650 Notch Receptors Human genes 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 108010075205 OVA-8 Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101100268917 Oryctolagus cuniculus ACOX2 gene Proteins 0.000 description 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 101800001821 Precursor of protein E3/E2 Proteins 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102100023361 SAP domain-containing ribonucleoprotein Human genes 0.000 description 1
- 102100029216 SLAM family member 5 Human genes 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- 108091006275 SLC5A7 Proteins 0.000 description 1
- 102100020814 Sequestosome-1 Human genes 0.000 description 1
- 108700015968 Slam family Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101710151717 Stress-related protein Proteins 0.000 description 1
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 1
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 1
- 102000050389 Syntaxin Human genes 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- UCONUSSAWGCZMV-UHFFFAOYSA-N Tetrahydro-cannabinol-carbonsaeure Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCCCC)C(C(O)=O)=C2O UCONUSSAWGCZMV-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
- 101150013568 US16 gene Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 108010055066 asparaginylendopeptidase Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 238000002624 low-dose chemotherapy Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 101800002664 p62 Proteins 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000000858 peroxisomal effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000025220 protein targeting to vacuole Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000031539 regulation of cell division Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 108060008004 synaptotagmin Proteins 0.000 description 1
- 102000003137 synaptotagmin Human genes 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
- 238000007704 wet chemistry method Methods 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
Definitions
- the field of the invention is compositions and methods of improved neoepitope-based immune therapeutics, especially as it relates to preparation of recombinant viral therapeutics for cancer therapy.
- Cancer immunotherapies targeting certain antigens common to a specific cancer have led to remarkable responses in some patients. Unfortunately, many patients failed to respond to such immunotherapy despite apparent expression of the same antigen. One possible reason for such failure could be that various effector cells of the immune system may not have been present in sufficient quantities, or may have been exhausted. Moreover, intracellular antigen processing and HLA variability among patients may have led to insufficient processing of the antigen and/or antigen display, leading to a therapeutically ineffective or lacking response.
- neoepitopes may provide a unique precision target for immunotherapy. Additionally, it has been shown that cytolytic T-cell responses can be triggered by very small quantities of peptides (e.g., Sykulev et al., Immunity , Volume 4, Issue 6, p 565-571, 1 Jun. 1996). Moreover, due to the relatively large number of mutations in many cancers, the number of possible targets is relatively high. In view of these findings, the identification of cancer neoepitopes as therapeutic targets has attracted much attention.
- the neoepitopes can be filtered for the type of mutation (e.g., to ascertain missense or nonsense mutation), the level of transcription to confirm transcription of the mutated gene, and to confirm protein expression. Moreover, the so filtered neoepitope may be further analyzed for specific binding to the patient's HLA system as described in WO 2016/172722. While such system advantageously reduces the relatively large number of potential neoepitopes, the significance of these neoepitopes with respect to treatment outcome remains uncertain.
- processing of precursor proteins to generate the neoepitopes is not fully understood and contributes as such to the lack of predictability of therapeutic success.
- the inventive subject matter is directed to various immune therapeutic compositions and methods, and especially recombinant viral expression systems, in which multiple selected neoepitopes are combined to form a rational-designed polypeptide with a trafficking signal to increase antigen processing and presentation and to so maximize therapeutic effect.
- the inventors contemplate a method of generating an expression vector for immune therapy.
- such method includes a step of constructing a recombinant nucleic acid that has a sequence that encodes a polytope that is operably linked to a promoter to drive expression of the polytope, wherein the polytope comprises multiple filtered neoepitope sequences.
- the polytope includes one or more trafficking elements to directs the expressed polytope to a specific sub-cellular location, such as the cytoplasm, the proteasome, the recycling endosome, the sorting endosome, the lysosome, or the extracellular membrane.
- the trafficking element may also direct the polytope to the extracellular space for secretion.
- the viral expression vector is an adenoviral expression vector having E1 and E2b genes deleted, and the promoter is a constitutive promoter.
- the promoter may also be an inducible promoter, and especially inducible under conditions that are common in a tumor microenvironment.
- suitable promoters may be inducible by hypoxia, IFN-gamma, and/or IL-8.
- trafficking element it is contemplated that all know trafficking elements are suitable, however, preferred trafficking elements include cleavable ubiquitin, non-cleavable ubiquitin, a CD1b leader sequence, a CD1a tail, a CD1c tail, and a LAMP1-transmembrane sequence.
- preferred trafficking elements include cleavable ubiquitin, non-cleavable ubiquitin, a CD1b leader sequence, a CD1a tail, a CD1c tail, and a LAMP1-transmembrane sequence.
- the filtered neoepitope sequences are filtered by comparing tumor versus matched normal of the same patient, by determination to have binding affinity to an MHC complex of equal or less than 200 nM, and/or the filtered neoepitope sequences are filtered against known human SNP and somatic variations.
- the filtered neoepitope sequences have an arrangement within the polytope such that the polytope has a likelihood of a presence and/or strength of hydrophobic sequences or signal peptides that is below a predetermined threshold.
- Contemplated filtered neoepitope sequences may bind to MHC-I (typically with an affinity of less than 200 nM) while the trafficking element directs the polytope to the cytoplasm or proteasome, or may bind to MHC-I (typically with an affinity of less than 200 nM) while the trafficking element directs the polytope to the recycling endosome, sorting endosome, or lysosome, or may bind to MHC-II (typically with an affinity of less than 200 nM) while the trafficking element directs the polytope to the recycling endosome, sorting endosome, or lysosome.
- MHC-I typically with an affinity of less than 200 nM
- the recombinant nucleic acid may further include a sequence that encodes a second polytope, wherein the second polytope comprises a second trafficking element that directs the second polytope to a different sub-cellular location and wherein the second polytope comprises a second plurality of filtered neoepitope sequences (e.g., at least some of the plurality of filtered neoepitope sequences and some of the second plurality of filtered neoepitope sequences are identical).
- the recombinant nucleic acid may also comprises a sequence that encodes one or more co-stimulatory molecules (e.g., CD80, CD86, CD30, CD40, CD30L, CD40L, ICOS-L, B7-H3, B7-H4, CD70, OX40L, 4-1BBL, GITR-L, TIM-3, TIM-4, CD48, CD58, TL1A, ICAM-1, LFA3), one or more immune stimulatory cytokines (e.g., IL-2, IL-12, IL-15, IL-15 super agonist (ALT803), IL-21, IPS1, and LMP1), and/or one or more proteins that interferes with or down-regulates checkpoint inhibition (e.g., antibody or an antagonist of CTLA-4, PD-1, TIM1 receptor, 2B4, or CD160).
- co-stimulatory molecules e.g., CD80, CD86, CD30, CD40, CD30L, CD40L, ICO
- the inventors also contemplate a recombinant expression vector for immune therapy that comprises a sequence that encodes a polytope (e.g., comprising a plurality of filtered neoepitope sequences) operably linked to a promoter to drive expression of the polytope.
- a polytope e.g., comprising a plurality of filtered neoepitope sequences
- the polytope includes a trafficking element that directs the polytope to a sub-cellular location (e.g., cytoplasm, recycling endosome, sorting endosome, lysosome, extracellular membrane), or the trafficking element directs the polytope to an extracellular space for secretion of the polytope.
- Preferred recombinant expression vectors are adenoviral expression vectors, especially having the E1 and E2b genes deleted. Such and other expression vectors may have a constitutive promoter, or an inducible promoter (preferably induced by hypoxia, IFN-gamma, or IL-8).
- the trafficking element is a cleavable ubiquitin, a non-cleavable ubiquitin, a CD1b leader sequence, a CD1a tail, a CD1c tail, and/or a LAMP1-transmembrane sequence.
- the sequences are filtered by comparing tumor versus matched normal of the same patient, filtered to have binding affinity to an MHC complex of equal or less than 200 nM, and/or filtered against known human SNP and somatic variations.
- the filtered neoepitope sequences have preferably an arrangement within the polytope such that the polytope has a likelihood of a presence and/or strength of hydrophobic sequences or signal peptides that is below a predetermined threshold to so avoid mis-directing the polytope.
- the filtered neoepitope sequences may bind to MHC-I (typically with an affinity of less than 200 nM) while the trafficking element directs the polytope to the cytoplasm or proteasome, or the filtered neoepitope sequences may bind to MHC-I (typically with an affinity of less than 200 nM) while the trafficking element directs the polytope to the recycling endosome, sorting endosome, or lysosome, or the filtered neoepitope sequences may bind to MHC-II (typically with an affinity of less than 200 nM) and wherein the trafficking element directs the polytope to the recycling endosome, sorting endosome, or lysosome.
- MHC-I typically with an affinity of less than 200 nM
- the recombinant nucleic acid may further include a sequence that encodes a second polytope, wherein the second polytope comprises a second trafficking element that directs the second polytope to a different sub-cellular location and wherein the second polytope comprises a second plurality of filtered neoepitope sequences.
- the second polytope comprises a second trafficking element that directs the second polytope to a different sub-cellular location and wherein the second polytope comprises a second plurality of filtered neoepitope sequences.
- the plurality of filtered neoepitope sequences and some of the second plurality of filtered neoepitope sequences are identical.
- the recombinant nucleic acid may further comprise a sequence that encodes one or more co-stimulatory molecules (e.g., CD80, CD86, CD30, CD40, CD30L, CD40L, ICOS-L, B7-H3, B7-H4, CD70, OX40L, 4-1BBL, GITR-L, TIM-3, TIM-4, CD48, CD58, TL1A, ICAM-1, LFA3), one or more immune stimulatory cytokines (e.g., IL-2, IL-12, IL-15, IL-15 super agonist (ALT803), IL-21, IPS1, and LMP1), and/or one or more proteins that interferes with or down-regulates checkpoint inhibition (e.g., antibody or an antagonist of CTLA-4, PD-1, TIM1 receptor, 2B4, or CD160).
- co-stimulatory molecules e.g., CD80, CD86, CD30, CD40, CD30L, CD40L, ICO
- the inventors also contemplate a recombinant virus that includes the recombinant vector as described herein.
- the virus is a replication deficient virus (e.g., adenovirus, preferably with deleted E1 and E2b gene).
- a virus may then be included in a pharmaceutical composition that is typically formulated for injection or intranasal administration. While not limiting to the inventive subject matter, such recombinant virus may then be used in the treatment of cancer, and/or in the manufacture of a medicament for treatment of cancer.
- the inventors also contemplate a method of treating an individual that typically includes a step of transfecting a cell of the individual with a recombinant virus, wherein the recombinant virus comprises a sequence that encodes a polytope operably linked to a promoter to drive expression of the polytope in the cell.
- the polytope comprises a trafficking element that directs the polytope to a sub-cellular location selected from the group consisting of cytoplasm, recycling endosome, sorting endosome, lysosome, and extracellular membrane, or the trafficking element directs the polytope to an extracellular space.
- the polytope in such methods comprises a plurality of filtered neoepitope sequences.
- the recombinant nucleic acid further may comprise a sequence that encodes a second polytope, wherein the second polytope comprises a second trafficking element that directs the second polytope to a different sub-cellular location and that the second polytope comprises a second plurality of filtered neoepitope sequences.
- a step of transfecting another cell of the individual with a second recombinant virus may be included, wherein the second recombinant virus comprises a second sequence that encodes a second polytope operably linked to a promoter to drive expression of the second polytope in the another cell, wherein the second polytope comprises a second trafficking element that directs the polytope to a second sub-cellular location selected from the group consisting of cytoplasm, recycling endosome, sorting endosome, lysosome, and extracellular membrane, or wherein the trafficking element directs the polytope to an extracellular space, and wherein the sub-cellular location and the second sub-cellular location are distinct, and wherein the second polytope comprises a second plurality of filtered neoepitope sequences.
- the plurality of filtered neoepitope sequences and some of the second plurality of filtered neoepitope sequences may be identical.
- Contemplated recombinant viruses in such methods may further comprises a sequence that encodes one or more co-stimulatory molecules (e.g., CD80, CD86, CD30, CD40, CD30L, CD40L, ICOS-L, B7-H3, B7-H4, CD70, OX40L, 4-1BBL, GITR-L, TIM-3, TIM-4, CD48, CD58, TL1A, ICAM-1, LFA3), one or more immune stimulatory cytokines (e.g., IL-2, IL-12, IL-15, IL-15 super agonist (ALT803), IL-21, IPS1, and LMP1), and/or one or more proteins that interferes with or down-regulates checkpoint inhibition (e.g., antibody or an antagonist of CTLA-4, PD-1, TIM1 receptor, 2B4, or CD160).
- co-stimulatory molecules e.g., CD80, CD86, CD30, CD40, CD30L, CD40L,
- the inventors also contemplate a method of biasing an immune response against a neoepitope in an individual towards a CD4+ biased immune response.
- Such method will typically include a step of transfecting a cell of the individual with a recombinant virus, wherein the recombinant virus comprises a sequence that encodes a polytope operably linked to a promoter to drive expression of the polytope in the cell, wherein the polytope comprises the neoepitope.
- the polytope comprises a trafficking element that directs the polytope to a sub-cellular location selected from the group consisting of a recycling endosome, a sorting endosome, and a lysosome.
- the polytope is expressed from the sequence, trafficked, and proteolytically processed to present the neoepitope on a MHC-II complex and to thereby stimulate CD4+ T-cells.
- Suitable neoepitope may be calculated to bind to MHC-I (typically with an affinity of less than 200 nM) or to bind to MHC-II (typically with an affinity of less than 200 nM), and/or suitable trafficking elements include a CD1b leader sequence, a CD1a tail, a CD1c tail, and a LAMP1-transmembrane sequence.
- the recombinant virus may further comprise a sequence that encodes at least one of a co-stimulatory molecule, an immune stimulatory cytokine, and a protein that interferes with or down-regulates checkpoint inhibition.
- the inventors also contemplate a method of biasing an immune response against a neoepitope in an individual towards a CD8+ biased immune response.
- Such method will typically include a step of transfecting a cell of the individual with a recombinant virus, wherein the recombinant virus comprises a sequence that encodes a polytope operably linked to a promoter to drive expression of the polytope in the cell, wherein the polytope comprises the neoepitope.
- the polytope comprises a trafficking element that directs the polytope to the proteasome.
- the polytope is expressed from the sequence, trafficked, and proteolytically processed to present the neoepitope on a MHC-I complex and to thereby stimulate CD8+ T-cells.
- Suitable neoepitope may be calculated to bind to MHC-I (typically with an affinity of less than 200 nM) or to bind to MHC-II (typically with an affinity of less than 200 nM), and/or suitable trafficking elements include a CD1b leader sequence, a CD1a tail, a CD1c tail, and a LAMP1-transmembrane sequence.
- the recombinant virus may further comprise a sequence that encodes at least one of a co-stimulatory molecule, an immune stimulatory cytokine, and a protein that interferes with or down-regulates checkpoint inhibition.
- the inventors contemplate a method of generating a polytope for immune therapy.
- Such method preferably comprises a step of obtaining a plurality of neoepitope sequences, and generating a set of polytope sequences, each having a distinct linear arrangement of the plurality of neoepitope sequences.
- a score is calculated that is representative for a likelihood of presence and/or strength of hydrophobic sequences or signal peptides, and in yet another step, the score is used to rank the polytope sequences.
- the linear arrangement of the plurality of neoepitope sequences is then selected on the basis of the rank.
- the score is calculated using at least one of a weight matrix and a neural network prediction, and/or the neoepitope sequences are filtered by at least one of MHC binding strength, known human SNP and somatic variations, and comparing tumor versus matched normal of the same patient.
- each of the polytope sequences comprises at least five neoepitope sequences.
- FIG. 1 is a schematic representation of various neoepitope arrangements.
- FIG. 2 is an exemplary and partial schematic for selecting preferred arrangements of neoepitopes.
- FIG. 3 is a schematic illustration of antigen processing in the cytoplasm and MHC-I presentation.
- FIG. 4 is a schematic illustration of antigen processing in the lysosomal and endosomal compartment and MHC-II presentation.
- FIGS. 5A-5C are exemplary sequence arrangements for class I antigen processing in the cytoplasm and MHC-I presentation.
- FIGS. 6A-6C are exemplary sequence arrangements for class I antigen processing in the cytoplasm and MHC-II presentation.
- FIGS. 7A-7C are exemplary sequence arrangements for class II antigen processing in the cytoplasm and MHC-II presentation.
- FIG. 8 is an exemplary prophylactic vaccination schedule for B16-F10 melanoma.
- FIGS. 9A-9C are graphs depicting exemplary results for the anti-tumor vaccination using subcutaneous injection of the vaccine.
- FIGS. 10A-10C are graphs depicting exemplary results for the anti-tumor vaccination using intravenous injection of the vaccine.
- neoepitope-based immune therapy can be further improved by targeting expressed patient- and tumor specific neoepitopes towards processing and/or specific cell surface presentation or even secretion, and that neoepitope-based therapy can still further be augmented using checkpoint inhibition, immune stimulation via cytokines, and/or inhibitors of myeloid derived suppressor cells (MDCS), T-regulatory cells (Tregs), or M2 macrophages.
- MDCS myeloid derived suppressor cells
- Tregs T-regulatory cells
- M2 macrophages M2 macrophages.
- therapeutic entities will be expressed in vivo from a recombinant nucleic acid, and especially suitable recombinant nucleic acid include plasmids and viral nucleic acids. Where a viral nucleic acid is employed, it is particularly preferred that the nucleic acid is delivered via infection of the patient or patient cells by the virus.
- compositions and methods presented herein will include one or more neoepitopes that are specific to the patient and the tumor in the patient to allow for targeted treatment.
- treatment may advantageously be tailored to achieve one or more specific immune reactions, including a CD4 + biased immune response, a CD8 + biased immune response, antibody biased immune response, and/or a stimulated immune response (e.g., reducing checkpoint inhibition and/or by activation of immune competent cells using cytokines).
- a stimulated immune response e.g., reducing checkpoint inhibition and/or by activation of immune competent cells using cytokines.
- Neoepitopes can be characterized as expressed random mutations in tumor cells that created unique and tumor specific antigens. Therefore, viewed from a different perspective, neoepitopes may be identified by considering the type (e.g., deletion, insertion, transversion, transition, translocation) and impact of the mutation (e.g., non-sense, missense, frame shift, etc.), which may as such serve as a content filter through which silent and other non-relevant (e.g., non-expressed) mutations are eliminated.
- type e.g., deletion, insertion, transversion, transition, translocation
- the mutation e.g., non-sense, missense, frame shift, etc.
- neoepitope sequences can be defined as sequence stretches with relatively short length (e.g., 8-12 mers or 14-20 mers) wherein such stretches will include the change(s) in the amino acid sequences. Most typically, but not necessarily, the changed amino acid will be at or near the central amino acid position.
- a typical neoepitope may have the structure of A 4 -N-A 4 , or A 3 -N-A 5 , or A 2 -N-A 7 , or A 5 -N-A 3 , or A 7 -N-A 2 , where A is a proteinogenic wild type or normal (i.e., from corresponding healthy tissue of the same patient) amino acid and N is a changed amino acid (relative to wild type or relative to matched normal). Therefore, the neoepitope sequences contemplated herein include sequence stretches with relatively short length (e.g., 5-30 mers, more typically 8-12 mers, or 14-20 mers) wherein such stretches include the change(s) in the amino acid sequences.
- additional amino acids may be placed upstream or downstream of the changed amino acid, for example, to allow for additional antigen processing in the various compartments (e.g., for proteasome processing in the cytosol, or specific protease processing in the endosomal and/or lysosomal compartments) of a cell.
- neoepitope sequences that include the changed amino acid, depending on the position of the changed amino acid.
- sequence variability allows for multiple choices of neoepitopes and as such increases the number of potentially useful targets that can then be selected on the basis of one or more desirable traits (e.g., highest affinity to a patient HLA-type, highest structural stability, etc.).
- neoepitopes will be calculated to have a length of between 2-50 amino acids, more typically between 5-30 amino acids, and most typically between 8-12 amino acids, or 14-20 amino acids, with the changed amino acid preferably centrally located or otherwise situated in a manner that improves its binding to MHC.
- a typical neoepitope length will be about 8-12 amino acids, while the typical neoepitope length for presentation via MHC-II complex will have a length of about 14-20 amino acids.
- the position of the changed amino acid in the neoepitope may be other than central, the actual peptide sequence and with that actual topology of the neoepitope may vary considerably, and the neoepitope sequence with a desired binding affinity to the MHC-I or MHC-II presentation and/or desired protease processing will typically dictate the particular sequence.
- neoepitopes may start with a variety of biological materials, including fresh biopsies, frozen, or otherwise preserved tissue or cell samples, circulating tumor cells, exosomes, various body fluids (and especially blood), etc. Therefore, suitable methods of omics analysis include nucleic acid sequencing, and particularly NGS methods operating on DNA (e.g., Illumina sequencing, ion torrent sequencing, 454 pyrosequencing, nanopore sequencing, etc.), RNA sequencing (e.g., RNAseq, reverse transcription based sequencing, etc.), and in some cases protein sequencing or mass spectroscopy based sequencing (e.g., SRM, MRM, CRM, etc.).
- DNA e.g., Illumina sequencing, ion torrent sequencing, 454 pyrosequencing, nanopore sequencing, etc.
- RNA sequencing e.g., RNAseq, reverse transcription based sequencing, etc.
- protein sequencing or mass spectroscopy based sequencing e.g., SRM, MRM, CRM,
- DNA analysis is performed by whole genome sequencing and/or exome sequencing (typically at a coverage depth of at least 10 ⁇ , more typically at least 20 ⁇ ) of both tumor and matched normal sample.
- DNA data may also be provided from an already established sequence record (e.g., SAM, BAM, FASTA, FASTQ, or VCF file) from a prior sequence determination of the same patient. Therefore, data sets suitable for use herein include unprocessed or processed data sets, and exemplary preferred data sets include those having BAM format, SAM format, GAR format, FASTQ format, or FASTA format, as well as BAMBAM, SAMBAM, and VCF data sets.
- the data sets are provided in BAM format or as BAMBAM diff objects as is described in US2012/0059670A1 and US2012/0066001A1.
- the data sets are reflective of a tumor and a matched normal sample of the same patient.
- genetic germ line alterations not giving rise to the tumor e.g., silent mutation, SNP, etc.
- the tumor sample may be from an initial tumor, from the tumor upon start of treatment, from a recurrent tumor and/or metastatic site, etc.
- the matched normal sample of the patient is blood, or a non-diseased tissue from the same tissue type as the tumor.
- the computational analysis of the sequence data may be performed in numerous manners. In most preferred methods, however, analysis is performed in silico by location-guided synchronous alignment of tumor and normal samples as, for example, disclosed in US 2012/0059670 and US 2012/0066001 using BAM files and BAM servers. Such analysis advantageously reduces false positive neoepitopes and significantly reduces demands on memory and computational resources.
- contemplated methods of processing enables BamBam to efficiently calculate overall copy number and infer regions of structural variation (for example, chromosomal translocations) in both tumor and germline genomes; to efficiently calculate overall and allele-specific copy number; infer regions exhibiting loss of heterozygosity (LOH); and discover both somatic and germline sequence variants (for example, point mutations) and structural rearrangements (for example, chromosomal fusions.
- LHO heterozygosity
- BamBam can also immediately distinguish somatic from germline sequence variants, calculate allele-specific copy number alterations in the tumor genome, and phase germline haplotypes across chromosomal regions where the allelic proportion has shifted in the tumor genome.
- a variant discovered is somatic (that is, a variant sequence found only in the tumor) or a germline (that is, a variant sequence that is inherited or heritable) variant requires that we compare the tumor and matched normal genomes in some way. This can be done sequentially, by summarizing data at every genomic position for both tumor and germline and then combining the results for analysis.
- whole-genome BAM files are hundreds of gigabytes in their compressed form (1-2 terabytes uncompressed), the intermediate results that would need to be stored for later analysis will be extremely large and slow to merge and analyze.
- BamBam reads from two files at the same time, constantly keeping each BAM file in synchrony with the other and piling up the genomic reads that overlap every common genomic location between the two files. For each pair of pileups, BamBam runs a series of analyses listed above before discarding the pileups and moving to the next common genomic location.
- the computer's RAM usage is minimal and processing speed is limited primarily by the speed that the filesystem can read the two files. This enables BamBam to process massive amounts of data quickly, while being flexible enough to run on a single computer or across a computer cluster.
- Another important benefit to processing these files with BamBam is that its output is fairly minimal, consisting only of the important differences found in each file. This produces what is essentially a whole-genome diff between the patient's tumor and germline genomes, requiring much less disk storage than it would take if all genome information was stored for each file separately.
- BamBam is a computationally efficient method for surveying large sequencing datasets to produce a set of high-quality genomic events that occur within each tumor relative to its germline.
- the object represents a digital object instantiated from the BamBam techniques and reflects a difference between a reference sequence (for example, a first sequence) and an analysis sequence (for example, a second sequence).
- Such a method is easily extendible to more than two related sequencing datasets. For example, if three samples, matched normal, tumor, and relapse, were sequenced, this method could be used to search for changes specific to the tumor & the relapse sample, and changes specific only to the relapse, suggesting the relapse tumor has changed somewhat from the original tumor from which it had presumably derived. Also, one could use this same method to determine the inherited portions of a child's genome given sequenced samples from child, father, and mother.
- Somatic and Germline Variant Calling Because BamBam keeps the sequence data in the pair of files in sync across the genome, a complex mutation model that requires sequencing data from both tumor and germline BAM files as well as the human reference can be implemented easily. This model aims to maximize the joint probability of both the germline genotype (given the germline reads and the reference nucleotide) and the genotype of the tumor (given the germline genotype, a simple mutation model, an estimate of the fraction of contaminating normal tissue in the tumor sample, and the tumor sequence data).
- the probability of the germline alleles given the germline genotype is modeled as a multinomial over the four nucleotides:
- P ⁇ ( D g ⁇ G g ) n ! n A ⁇ ! n T ⁇ ! n G ⁇ ! n C ! ⁇ ⁇ i n ⁇ P ⁇ ( d g i ⁇ G g )
- n is the total number of germline reads at this position and nA, nG, nC, nT are the reads supporting each observed allele.
- Gg) are assumed to be independent, coming from either of the two parental alleles represented by the genotype Gg, while also incorporating the approximate base error rate of the sequencer.
- the prior on the germline genotype is conditioned on the reference base as P ( G g
- the germline prior does not incorporate any information on known, inherited SNPs.
- the probability of the set of tumor reads is again defined as multinomial
- the tumor and germline genotypes, G t max , G g maxi , selected are those that maximize (1), and the posterior probability defined by
- any language directed to a computer should be read to include any suitable combination of computing devices, including servers, interfaces, systems, databases, agents, peers, engines, controllers, or other types of computing devices operating individually or collectively.
- the computing devices comprise a processor configured to execute software instructions stored on a tangible, non-transitory computer readable storage medium (e.g., hard drive, solid state drive, RAM, flash, ROM, etc.).
- the software instructions preferably configure the computing device to provide the roles, responsibilities, or other functionality as discussed below with respect to the disclosed apparatus.
- the disclosed technologies can be embodied as a computer program product that includes a non-transitory computer readable medium storing the software instructions that causes a processor to execute the disclosed steps associated with implementations of computer-based algorithms, processes, methods, or other instructions.
- the various servers, systems, databases, or interfaces exchange data using standardized protocols or algorithms, possibly based on HTTP, HTTPS, AES, public-private key exchanges, web service APIs, known financial transaction protocols, or other electronic information exchanging methods.
- Data exchanges among devices can be conducted over a packet-switched network, the Internet, LAN, WAN, VPN, or other type of packet switched network; a circuit switched network; cell switched network; or other type of network.
- a patient- and cancer-specific in silico collection of sequences can be established that encode neoepitopes having a predetermined length of, for example, between 5 and 25 amino acids and include at least one changed amino acid.
- Such collection will typically include for each changed amino acid at least two, at least three, at least four, at least five, or at least six members in which the position of the changed amino acid is not identical.
- Such collection advantageously increases potential candidate molecules suitable for immune therapy and can then be used for further filtering (e.g., by sub-cellular location, transcription/expression level, MHC-I and/or II affinity, etc.) as is described in more detail below.
- cancer neoepitopes from a variety of cancers and patients, including the following cancer types: BLCA, BRCA, CESC, COAD, DLBC, GBM, HNSC, KICH, KIRC, KIRP, LAML, LGG, LIHC, LUAD, LUSC, OV, PRAD, READ, SARC, SKCM, STAD, THCA, and UCEC.
- Exemplary neoepitope data for these cancers can be found in International application PCT/US16/29244, incorporated by reference herein.
- neoepitopes will necessarily lead to a therapeutically equally effective reaction in a patient. Indeed, it is well known in the art that only a fraction of neoepitopes will generate an immune response. To increase likelihood of a therapeutically desirable response, the initially identified neoepitopes can be further filtered. Of course, it should be appreciated that downstream analysis need not take into account silent mutations for the purpose of the methods presented herein.
- preferred mutation analyses will provide in addition to the particular type of mutation (e.g., deletion, insertion, transversion, transition, translocation) also information of the impact of the mutation (e.g., non-sense, missense, etc.) and may as such serve as a first content filter through which silent mutations are eliminated.
- neoepitopes can be selected for further consideration where the mutation is a frame-shift, non-sense, and/or missense mutation.
- neoepitopes may also be subject to detailed analysis for sub-cellular location parameters. For example, neoepitope sequences may be selected for further consideration if the neoepitopes are identified as having a membrane associated location (e.g., are located at the outside of a cell membrane of a cell) and/or if an in silico structural calculation confirms that the neoepitope is likely to be solvent exposed, or presents a structurally stable epitope (e.g., J Exp Med 2014), etc.
- a membrane associated location e.g., are located at the outside of a cell membrane of a cell
- an in silico structural calculation confirms that the neoepitope is likely to be solvent exposed, or presents a structurally stable epitope (e.g., J Exp Med 2014), etc.
- neoepitopes are especially suitable for use herein where omics (or other) analysis reveals that the neoepitope is actually expressed. Identification of expression and expression level of a neoepitope can be performed in all manners known in the art and preferred methods include quantitative RNA (hnRNA or mRNA) analysis and/or quantitative proteomics analysis.
- the threshold level for inclusion of neoepitopes will be an expression level of at least 20%, at least 30%, at least 40%, or at least 50% of expression level of the corresponding matched normal sequence, thus ensuring that the (neo)epitope is at least potentially ‘visible’ to the immune system. Consequently, it is generally preferred that the omics analysis also includes an analysis of gene expression (transcriptomic analysis) to so help identify the level of expression for the gene with a mutation.
- RNA sequence information may be obtained from reverse transcribed polyA + -RNA, which is in turn obtained from a tumor sample and a matched normal (healthy) sample of the same patient.
- polyA + -RNA is typically preferred as a representation of the transcriptome
- other forms of RNA hn-RNA, non-polyadenylated RNA, siRNA, miRNA, etc.
- RNA quantification and sequencing is performed using RNAseq, qPCR and/or rtPCR based methods, although various alternative methods (e.g., solid phase hybridization-based methods) are also deemed suitable.
- transcriptomic analysis may be suitable (alone or in combination with genomic analysis) to identify and quantify genes having a cancer- and patient-specific mutation.
- proteomics analysis can be performed in numerous manners to ascertain actual translation of the RNA of the neoepitope, and all known manners of proteomics analysis are contemplated herein.
- particularly preferred proteomics methods include antibody-based methods and mass spectroscopic methods.
- the proteomics analysis may not only provide qualitative or quantitative information about the protein per se, but may also include protein activity data where the protein has catalytic or other functional activity.
- One exemplary technique for conducting proteomic assays is described in U.S. Pat. No. 7,473,532, incorporated by reference herein.
- SRM selective reaction monitoring
- MRM multiple reaction monitoring
- CCM consecutive reaction monitoring
- the neoepitopes may be compared against a database that contains known human sequences (e.g., of the patient or a collection of patients) to so avoid use of a human-identical sequence.
- filtering may also include removal of neoepitope sequences that are due to SNPs in the patient where the SNPs are present in both the tumor and the matched normal sequence.
- dbSNP The Single Nucleotide Polymorphism Database
- NCBI National Center for Biotechnology Information
- NHGRI National Human Genome Research Institute
- SNPs single nucleotide polymorphisms
- STRs microsatellite markers or short tandem repeats
- MNPs multinucleotide polymorphisms
- heterozygous sequences and (6) named variants.
- the dbSNP accepts apparently neutral polymorphisms, polymorphisms corresponding to known phenotypes, and regions of no variation.
- the patient and tumor specific neoepitopes may be filtered to remove those known sequences, yielding a sequence set with a plurality of neoepitope sequences having substantially reduced false positives.
- a further filtering step is contemplated that takes into account the gene type that is affected by the neoepitope.
- suitable gene types include cancer driver genes, genes associated with regulation of cell division, genes associated with apoptosis, and genes associated with signal transduction.
- cancer driver genes are particularly preferred (which may span by function a variety of gene types, including receptor genes, signal transduction genes, transcription regulator genes, etc.).
- suitable gene types may also be known passenger genes and genes involved in metabolism.
- Suitable algorithms include MutsigCV ( Nature 2014, 505(7484):495-501), ActiveDriver ( Mol Syst Biol 2013, 9:637), MuSiC ( Genome Res 2012, 22(8):1589-1598), OncodriveClust ( Bioinformatics 2013, 29(18):2238-2244), OncodriveFM ( Nucleic Acids Res 2012, 40(21):e169), OncodriveFML ( Genome Biol 2016, 17(1):128), Tumor Suppressor and Oncogenes (TUSON) ( Cell 2013, 155(4):948-962), 20/20+ (https://github.com/KarchinLab/2020plus), and oncodriveROLE ( Bioinformatics (2014) 30 (17): i549-i555).
- identification of cancer driver genes may also employ various sources for known cancer driver genes and their association with specific cancers.
- the Intogen Catalog of driver mutations (2016.5; URL: www.intogen.org) contains the results of the driver analysis performed by the Cancer Genome Interpreter across 6,792 exomes of a pan-cancer cohort of 28 tumor types.
- neoepitopes will be visible to the immune system as the neoepitopes also need to be processed where present in a larger context (e.g., within a polytope) and presented on the MHC complex of the patient. In that context, it must be appreciated that only a fraction of all neoepitopes will have sufficient affinity for presentation. Consequently, and especially in the context of immune therapy it should be apparent that neoepitopes will be more likely effective where the neoepitopes are properly processed, bound to, and presented by the MHC complexes.
- neoepitopes that can be presented via the MHC complex, wherein such neoepitopes have a minimum affinity to the patient's HLA-type. Consequently, it should be appreciated that effective binding and presentation is a combined function of the sequence of the neoepitope and the particular HLA-type of a patient. Therefore, HLA-type determination of the patient tissue is typically required.
- the HLA-type determination includes at least three MHC-I sub-types (e.g., HLA-A, HLA-B, HLA-C) and at least three MHC-II sub-types (e.g., HLA-DP, HLA-DQ, HLA-DR), preferably with each subtype being determined to at least 2-digit or at least 4-digit depth.
- MHC-I sub-types e.g., HLA-A, HLA-B, HLA-C
- MHC-II sub-types e.g., HLA-DP, HLA-DQ, HLA-DR
- each subtype being determined to at least 2-digit or at least 4-digit depth.
- greater depth e.g., 6 digit, 8 digit
- a structural solution for the HLA-type is calculated and/or obtained from a database, which is then used in a docking model in silico to determine binding affinity of the (typically filtered) neoepitope to the HLA structural solution.
- suitable systems for determination of binding affinities include the NetMHC platform (see e.g., Nucleic Acids Res. 2008 Jul. 1; 36(Web Server issue): W509-W512.).
- Neoepitopes with high affinity e.g., less than 100 nM, less than 75 nM, less than 50 nM are then selected for therapy creation, along with the knowledge of the patient's MHC-I/II subtype.
- HLA determination can be performed using various methods in wet-chemistry that are well known in the art, and all of these methods are deemed suitable for use herein.
- the HLA-type can also be predicted from omics data in silico using a reference sequence containing most or all of the known and/or common HLA-types.
- a relatively large number of patient sequence reads mapping to chromosome 6p21.3 is provided by a database or sequencing machine. Most typically the sequence reads will have a length of about 100-300 bases and comprise metadata, including read quality, alignment information, orientation, location, etc.
- suitable formats include SAM, BAM, FASTA, GAR, etc. While not limiting to the inventive subject matter, it is generally preferred that the patient sequence reads provide a depth of coverage of at least 5 ⁇ , more typically at least 10 ⁇ , even more typically at least 20 ⁇ , and most typically at least 30 ⁇ .
- contemplated methods further employ one or more reference sequences that include a plurality of sequences of known and distinct HLA alleles.
- a typical reference sequence may be a synthetic (without corresponding human or other mammalian counterpart) sequence that includes sequence segments of at least one HLA-type with multiple HLA-alleles of that HLA-type.
- suitable reference sequences include a collection of known genomic sequences for at least 50 different alleles of HLA-A.
- the reference sequence may also include a collection of known RNA sequences for at least 50 different alleles of HLA-A.
- the reference sequence is not limited to 50 alleles of HLA-A, but may have alternative composition with respect to HLA-type and number/composition of alleles.
- the reference sequence will be in a computer readable format and will be provided from a database or other data storage device.
- suitable reference sequence formats include FASTA, FASTQ, EMBL, GCG, or GenBank format, and may be directly obtained or built from data of a public data repository (e.g., IMGT, the International ImMunoGeneTics information system, or The Allele Frequency Net Database, EUROSTAM, URL: www.allelefrequencies.net).
- the reference sequence may also be built from individual known HLA-alleles based on one or more predetermined criteria such as allele frequency, ethnic allele distribution, common or rare allele types, etc.
- each individual carries two alleles for each HLA-type, and that these alleles may be very similar, or in some cases even identical. Such high degree of similarity poses a significant problem for traditional alignment schemes.
- the de Bruijn graph is constructed by decomposing a sequence read into relatively small k-mers (typically having a length of between 10-20 bases), and by implementing a weighted vote process in which each patient sequence read provides a vote (“quantitative read support”) for each of the alleles on the basis of k-mers of that sequence read that match the sequence of the allele.
- the cumulatively highest vote for an allele then indicates the most likely predicted HLA allele.
- each fragment that is a match to the allele is also used to calculate the overall coverage and depth of coverage for that allele.
- Scoring may further be improved or refined as needed, especially where many of the top hits are similar (e.g., where a significant portion of their score comes from a highly shared set of k-mers).
- score refinement may include a weighting scheme in which alleles that are substantially similar (e.g., >99%, or other predetermined value) to the current top hit are removed from future consideration. Counts for k-mers used by the current top hit are then re-weighted by a factor (e.g., 0.5), and the scores for each HLA allele are recalculated by summing these weighted counts. This selection process is repeated to find a new top hit.
- a factor e.g., 0.5
- DNA or RNA, or a combination of both DNA and RNA can be processed to make HLA predictions that are highly accurate and can be derived from tumor or blood DNA or RNA.
- suitable methods and considerations for high-accuracy in silico HLA typing are described in WO 2017/035392, incorporated by reference herein.
- HLA-matched neoepitopes can be biochemically validated in vitro prior to inclusion of the nucleic acid encoding the epitope as payload into the virus as is further discussed below.
- matching of the patient's HLA-type to the patient- and cancer-specific neoepitope can be done using systems other than NetMHC, and suitable systems include NetMHC II, NetMHCpan, IEDB Analysis Resource (URL immuneepitope.org), RankPep, PREDEP, SVMHC, Epipredict, HLABinding, and others (see e.g., J Immunol Methods 2011; 374:1-4).
- the collection of neoepitope sequences in which the position of the altered amino acid is moved can be used.
- modifications to the neoepitopes may be implemented by adding N- and/or C-terminal modifications to further increase binding of the expressed neoepitope to the patient's HLA-type.
- neoepitopes may be native as identified or further modified to better match a particular HLA-type.
- binding of corresponding wild type sequences i.e., neoepitope sequence without amino acid change
- binding of corresponding wild type sequences can be calculated to ensure high differential affinities.
- especially preferred high differential affinities in MHC binding between the neoepitope and its corresponding wild type sequence are at least 2-fold, at least 5-fold, at least 10-fold, at least 100-fold, at least 500-fold, at least 1000-fold, etc.).
- Binding affinity, and particularly differential binding affinity may also be determined in vitro using various systems and methods.
- antigen presenting cells of a patient or cells with matched HLA-type can be transfected with a nucleic acid (e.g., viral, plasmid, linear DNA, RNA, etc.) to express one or more neoepitopes using constructs as described in more detail below.
- a nucleic acid e.g., viral, plasmid, linear DNA, RNA, etc.
- the neoepitopes can then be identified in the MHC complex on the outside of the cell, either using specific binders to the neoepitope or using a cell based system (e.g., PBMC of the patient) in which T cell activation or cytotoxic NK cell activity can be observed in vitro.
- Neoepitopes with differential activity elicit a stronger signal or immune response as compared to the corresponding wild type epitope will then be selected for therapy creation.
- one or more immune therapeutic agents may be prepared using the sequence information of the neoepitope.
- the patient may be treated with a virus that is genetically modified with a nucleic acid construct as further discussed below that leads to expression of at least one of the identified neoepitopes to initiate an immune response against the tumor.
- suitable viruses include adenoviruses, adeno-associated viruses, alphaviruses, herpes viruses, lentiviruses, etc.
- adenoviruses are particularly preferred.
- the virus is a replication deficient and non-immunogenic virus, which is typically accomplished by targeted deletion of selected viral proteins (e.g., E1, E3 proteins).
- selected viral proteins e.g., E1, E3 proteins.
- Such desirable properties may be further enhanced by deleting E2b gene function, and high titers of recombinant viruses can be achieved using genetically modified human 293 cells as has been recently reported (e.g., J Virol. 1998 February; 72(2): 926-933).
- the virus may be used to infect patient (or non-patient) cells ex vivo or in vivo.
- the virus may be injected subcutaneously or intravenously, or may be administered intranasally or via inhalation to so infect the patients cells, and especially antigen presenting cells.
- immune competent cells e.g., NK cells, T cells, macrophages, dendritic cells, etc.
- the patient or from an allogeneic source
- immune therapy need not rely on a virus but may be effected with nucleic acid transfection or vaccination using RNA or DNA, or other recombinant vector that leads to the expression of the neoepitopes (e.g., as single peptides, tandem mini-gene, etc.) in desired cells, and especially immune competent cells.
- RNA or DNA or other recombinant vector that leads to the expression of the neoepitopes (e.g., as single peptides, tandem mini-gene, etc.) in desired cells, and especially immune competent cells.
- suitable promoter elements include constitutive strong promoters (e.g., SV40, CMV, UBC, EF1A, PGK, CAGG promoter), but inducible promoters are also deemed suitable for use herein, particularly where induction conditions are typical for a tumor microenvironment.
- inducible promoters include those sensitive to hypoxia and promoters that are sensitive to TGF- ⁇ or IL-8 (e.g., via TRAF, JNK, Erk, or other responsive elements promoter).
- suitable inducible promoters include the tetracycline-inducible promoter, the myxovirus resistance 1 (Mx1) promoter, etc.
- neoepitope arrangement and rational-designed trafficking of the neoepitopes can have a substantial impact on the efficacy of various immune therapeutic compositions.
- single neoepitopes can be expressed individually from the respective recombinant constructs that are delivered as a single plasmid, viral expression construct, etc.
- multiple neoepitopes can be separately expressed from individual promoters t form individual mRNA that are then individually translated into the respective neoepitopes, or from a single mRNA comprising individual translation starting points for each neoepitope sequence (e.g., using 2A or IRES signals).
- individual promoters t form individual mRNA that are then individually translated into the respective neoepitopes, or from a single mRNA comprising individual translation starting points for each neoepitope sequence (e.g., using 2A or IRES signals).
- 2A or IRES signals individual translation starting points for each neoepitope sequence
- neoepitopes were expressed from a single transcript to so form a single transcript that is then translated into a single polytope (i.e., polypeptide with a series of concatemerically linked neoepitopes, optionally with intervening linker sequences) expression, processing, and antigen presentation was found to be effective.
- polytope i.e., polypeptide with a series of concatemerically linked neoepitopes, optionally with intervening linker sequences
- polytopes requires processing by the appropriate proteases (e.g., proteasome, endosomal proteases, lysosomal proteases) within a cell to yield the neoepitope sequences, and polytopes led to improved antigen processing and presentation for most neoepitopes as compared to expression of individual neoepitopes, particularly where the individual neoepitopes had a relatively short length (e.g., less than 25 amino acids; results not shown).
- proteases e.g., proteasome, endosomal proteases, lysosomal proteases
- polytopes may be designed that include not only linker sequences to spatially separate neoepitopes, but also sequence portions (e.g., between 3-15 amino acids) that will be preferentially cleaved by a specific protease.
- nucleic acids and expression vectors that comprise a nucleic acid segment that encodes a polytope wherein the polytope is operably coupled to a desired promoter element, and wherein individual neoepitopes are optionally separated by a linker and/or protease cleavage or recognition sequence.
- FIG. 1 exemplarily illustrates various contemplated arrangements for neoepitopes for expression from an adenoviral expression system (here: AdV5, with deletion of E1 and E2b genes).
- Construct 1 exemplarily illustrates a neoepitope arrangement that comprises eight neoepitopes (‘minigene’) with a total length of 15 amino acids in concatemeric series without intervening linker sequences
- Construct 2 shows the arrangement of Construct 1 but with inclusion of nine amino acid linkers between each neoepitope sequence.
- the exact length of the neoepitope sequence is not limited to 15 amino acids, and that the exact length may vary considerably. However, in most cases, where neoepitope sequences of between 8-12 amino acids are flanked by additional amino acids, the total length will typically not exceed 25 amino acids, or 30 amino acids, or 50 amino acids.
- FIG. 1 denotes G-S linkers
- various other linker sequences are also suitable for use herein.
- Such relatively short neoepitopes are especially beneficial where presentation of the neoepitope is intended to be via the MHC-I complex.
- linker sequences will provide steric flexibility and separation of two adjacent neoepitopes.
- care must be taken to as to not chose amino acids for the linker that could be immunogenic/form an epitope that is already present in a patient. Consequently, it is generally preferred that the polytope construct is filtered once more for the presence of epitopes that could be found in a patient (e.g., as part of normal sequence or due to SNP or other sequence variation). Such filtering will apply the same technology and criteria as already discussed above.
- Construct 3 exemplarily illustrates a neoepitope arrangement that includes eight neoepitopes in concatemeric series without intervening linker sequences
- Construct 4 shows the arrangement of Construct 3 with inclusion of nine amino acid linkers between each neoepitope sequence.
- the exact length of such neoepitope sequences is not limited to 25 amino acids, and that the exact length may vary considerably. However, in most cases, where neoepitope sequences of between 14-20 amino acids are flanked by additional amino acids, the total length will typically not exceed 30 amino acids, or 45 amino acids, or 60 amino acids.
- the 15-aa minigenes are MHC Class I targeted tumor mutations selected with 7 amino acids of native sequence on either side
- the 25-aa minigenes are MHC Class II targeted tumor mutations selected with 12 amino acids of native sequence on either side.
- the exemplary 9 amino acid linkers are deemed to have sufficient length such that “unnatural” MHC Class I epitopes will not form between adjacent minigenes. Polytope sequences tended to be processed and presented more efficiently than single neoepitopes (data not shown), and addition of amino acids beyond 12 amino acids for MHC-I presentation and addition of amino acids beyond 20 amino acids for MHC-I presentation appeared to allow for somewhat improved protease processing.
- neoepitope sequences may be arranged in a manner to minimize hydrophobic sequences that may direct trafficking to the cell membrane or into the extracellular space.
- hydrophobic sequence or signal peptide detection is done either by comparison of sequences to a weight matrix (see e.g., Nucleic Acids Res. 1986 Jun. 11; 14(11): 4683-4690) or by using neural networks trained on peptides that contain signal sequences (see e.g., Journal of Molecular Biology 2004, Volume 338, Issue 5, 1027-1036).
- FIG. 2 depicts an exemplary scheme of arrangement selection in which a plurality of polytope sequences are analyzed.
- all positional permutations of all neoepitopes are calculated to produce a collection of arrangements. This collection is then processed through a weight matrix and/or neural network prediction to generate a score representing the likelihood of presence and/or strength of hydrophobic sequences or signal peptides. All positional permutations are then ranked by score, and the permutation(s) with a score below a predetermined threshold or lowest score for likelihood of presence and/or strength of hydrophobic sequences or signal peptides is/are used to construct a customized neoepitope expression cassette.
- the polytope comprise at least two, or at least three, or at least five, or at least eight, or at least ten neoepitope sequences.
- the payload capacity of the recombinant DNA is generally contemplated the limiting factor, along with the availability of filtered and appropriate neoepitopes. Therefore, adenoviral expression vectors, and particularly Adv5 are especially preferred as such vectors can accommodate up to 14 kb in recombinant payload.
- the neoepitopes/polytopes can be directed towards a specific sub-cellular compartment (e.g., cytosol, endosome, lysosome), and with that, towards a particular MHC presentation type.
- a specific sub-cellular compartment e.g., cytosol, endosome, lysosome
- Such directed expression, processing, and presentation is particularly advantageous as contemplated compositions may be prepared that direct an immune response towards a CD8 + type response (where the polytope is directed to the cytoplasmic space) or towards a CD4 + type response (where the polytope is directed to the endosomal/lysosomal compartment).
- neoepitope and polytope sequences may be designed and directed to one or both MHC presentation pathways using suitable sequence elements.
- routing the so expressed neoepitopes to the desired MHC-system it is noted that the MHC-I presented peptides will typically arise from the cytoplasm via proteasome processing and delivery through the endoplasmatic reticulum.
- MHC-II presented peptides will typically arise from the endosomal and lysosomal compartment via degradation and processing by acidic proteases (e.g., legumain, cathepsin L and cathepsin S) prior to delivery to the cell membrane.
- acidic proteases e.g., legumain, cathepsin L and cathepsin S
- proteolytic degradation of the polytope can also be enhanced using various methods, and especially contemplated methods include addition of a cleavable or non-cleavable ubiquitin moiety to the N-terminus, and/or placement of one or more destabilizing amino acids (e.g., N, K, C, F, E, R, Q) to the N-terminus of the polytope where the presentation is directed towards MHC-I.
- destabilizing amino acids e.g., N, K, C, F, E, R, Q
- cleavage sites for particular endosomal or lysosomal proteases can be engineered into the polytope to so facilitate of promote antigen processing.
- signal and/or leader peptides may be used for trafficking neoepitopes and/or polytopes to the endosomal and lysosomal compartment, or for retention in the cytoplasmic space.
- a leader peptide such as the CD1b leader peptide may be employed to sequester the (nascent) protein from the cytoplasm.
- targeting presequences and/or targeting peptides can be employed.
- the presequences of the targeting peptide may be added to the N-terminus and/or C-terminus and typically comprise between 6-136 basic and hydrophobic amino acids.
- the targeting sequence may be at the C-terminus.
- Other signals e.g., signal patches
- sequence elements that are separate in the peptide sequence and become functional upon proper peptide folding.
- protein modifications like glycosylations can induce targeting.
- PTS1 peroxisome targeting signal 1
- PTS2 peroxisome targeting signal 2
- sorting of proteins to endosomes and lysosomes may also be mediated by signals within the cytosolic domains of the proteins, typically comprising short, linear sequences. Some signals are referred to as tyrosine-based sorting signals and conform to the NPXY or YXX ⁇ consensus motifs. Other signals known as dileucine-based signals fit [DE]XXXL[LI] or DXXLL consensus motifs. All of these signals are recognized by components of protein coats peripherally associated with the cytosolic face of membranes.
- YXX ⁇ and [DE]XXXL[LI] signals are recognized with characteristic fine specificity by the adaptor protein (AP) complexes AP-1, AP-2, AP-3, and AP-4, whereas DXXLL signals are recognized by another family of adaptors known as GGAs.
- AP adaptor protein
- FYVE domain can be added, which has been associated with vacuolar protein sorting and endosome function.
- endosomal compartments can also be targeted using human CD1 tail sequences (see e.g., Immunology, 122, 522-531).
- lysosomal targeting can be achieved using a LAMP1-TM (transmembrane) sequence, while recycling endosomes can be targeted via the CD1a tail targeting sequence, and sorting endosomes can be targeted via the CD1c tail targeting sequence as is shown in more detail further below.
- LAMP1-TM transmembrane
- the polytope may also be designed as a chimeric polytope that includes at least a portion of, and more typically an entire tumor associated antigen (e.g., CEA, PSMA, PSA, MUC1, AFP, MAGE, HER2, HCC1, p62, p90, etc.).
- tumor associated antigens are generally processed and presented via the MHC-II pathway. Therefore, instead of using compartment specific signal sequences and/or leader sequences, the processing mechanism for tumor associated antigens can be employed for MHC-II targeting.
- N- or C-terminal cytoplasmic retention signals may be added, including a membrane-anchored protein or a membrane anchor domain of a membrane-anchored protein such that the protein is retained in the cell facing the cytosol.
- membrane-anchored proteins include SNAP-25, syntaxin, synaptoprevin, synaptotagmin, vesicle associated membrane proteins (VAMPs), synaptic vesicle glycoproteins (SV2), high affinity choline transporters, Neurexins, voltage-gated calcium channels, acetylcholinesterase, and NOTCH.
- the polytope may also comprise one or more transmembrane segments that will direct the neoepitope after processing to the outside of the cell membrane to so be visible to immune competent cells.
- transmembrane domains known in the art, and all of those are deemed suitable for use herein, including those having a single alpha helix, multiple alpha helices, alpha/beta barrels, etc.
- contemplated transmembrane domains can comprise comprises the transmembrane region(s) of the alpha, beta, or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8 (e.g., CD8 alpha, CD8 beta), CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2R beta, IL2R gamma, IL7R ⁇ , ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d,
- the recombinant chimeric gene has a first portion that encodes the transmembrane region(s), wherein the first portion is cloned in frame with a second portion that encodes the inhibitory protein. It should be noted that such presentation will not result in MHC-complex presentation and as such provides a neoepitope presentation independent of MHC/T-cell receptor interaction, which may further open additional avenues for immune recognition and trigger antibody production against the neoepitopes.
- the polytope may also be designed to include signal sequences for protein export of one or more neoepitope to thereby force a transfected cell to produce and secrete one or more neoepitopes.
- the SPARC leader sequence may be added to a neoepitope or polytope sequence, leading to in vivo secretion of the neoepitope or polytope sequence into the extracellular space.
- secreted neoepitopes or polytopes are then taken up by immune competent cells, and especially antigen presenting cells and dendritic cells, that in turn process and display the neoepitopes, typically via MHC-II pathways.
- the neoepitope or polytope may also be administered as peptide, optionally bound to a carrier protein to so act as a peptide vaccine.
- a carrier protein to so act as a peptide vaccine.
- suitable carrier proteins human albumin or lactoferrin are particularly preferred.
- Such carrier proteins may be in native conformation, or pretreated to form nanoparticles with exposed hydrophobic domains (see e.g., Adv Protein Chem Struct Biol. 2015; 98:121-43) to which the neoepitope or polytope can be coupled. Most typically, coupling of the neoepitope or polytope to the carrier protein will be non-covalent.
- carrier protein-bound neoepitopes or polytopes will be taken up by the immune competent cells, and especially antigen presenting cells and dendritic cells, that in turn process and display the neoepitopes, typically via MHC-II pathways.
- immune therapeutic compositions may be prepared that can deliver one or more neoepitopes to various sub-cellular locations, and with that generate distinct immune responses.
- FIG. 3 schematically illustrates a scenario where the polytope is predominantly processed in the proteasome of the cytoplasm and presented via the MHC-I complex, which is recognized by the T-cell receptor of a CD8 + T-cell. Consequently, targeting polytope processing to the cytosolic compartment will skew the immune response towards a CD8 + type response.
- Prior Art FIG. 3 schematically illustrates a scenario where the polytope is predominantly processed in the proteasome of the cytoplasm and presented via the MHC-I complex, which is recognized by the T-cell receptor of a CD8 + T-cell. Consequently, targeting polytope processing to the cytosolic compartment will skew the immune response towards a CD8 + type response.
- FIG. 4 schematically illustrates a scenario where the polytope is predominantly processed in the endosomal compartment and presented via the MHC-II complex, which is recognized by the T-cell receptor of a CD4 + T-cell. Consequently, targeting polytope processing to the endosomal or lysosomal compartment will skew the immune response towards a CD4 + type response.
- targeting methods allow for specific delivery of a polytope or neoepitope peptide to an MHC subtype having the highest affinity with the peptide, even if that peptide would otherwise not be presented by that MHC subtype.
- peptides for MHC-I presentation will generally be designed to have 8-12 amino acids (plus additional amino acids for flexibility in protease processing), while peptides for MHC-II presentation will be designed to have 14-20 amino acids (plus additional amino acids for flexibility in protease processing).
- further amino acids were added to allow for processing flexibility in the cytoplasmic, proteasome, or endosomal compartments.
- trafficking modes of the neoepitope or polytope may be combined to accommodate one or more specific purposes.
- sequential administration of the same neoepitopes or polytope with different targeting may be particularly beneficial in a prime-boost regimen where in a first administration the patient in inoculated with a recombinant virus to infect the patients cells, leading to antigen expression, processing, and presentation (e.g., predominantly MHC-I presentation) that will result in a first immune response originating from within a cell.
- the second administration of the same neoepitopes bound to albumin may then be employed as a boost as the so delivered protein is taken up by antigen presenting cells, leading in most cases to a distinct antigen presentation (e.g., predominantly MHC-II presentation).
- a distinct antigen presentation e.g., predominantly MHC-II presentation.
- ADCC responses or NK mediated cell killing may be promoted.
- immunogenicity of neoepitopes may be enhanced by cross presentation or MHC-II directed presentation.
- cancer cell neoepitopes are typically internally generated and recycled, and with that preferentially presented via the MHC-I system, contemplated systems and methods now allow for presentation of such neoepitopes via MHC-II, which may be more immunogenic as is shown in more detail below.
- MHC-II multiple and distinct trafficking of the same neoepitopes or polytopes may advantageously increase or supplement an immune response due to the stimulation of various and distinct components of the cellular and humoral immune system.
- neoepitopes or polytopes may be achieved in numerous manners.
- differently trafficked neoepitopes or polytopes may be administered separately using the same (e.g., viral expression vector) or different (e.g., viral expression vector and albumin bound) modality.
- the recombinant nucleic acid may include two distinct portions that encode the same, albeit differently trafficked neoepitope or polytope (e.g., first portion trafficked to first location (e.g., cytosol or endosomal or lysosomal), second portion trafficked to a second, distinct location (e.g., cytosol or endosomal or lysosomal, secreted, membrane bound)).
- first portion trafficked to first location e.g., cytosol or endosomal or lysosomal
- second portion trafficked to a second, distinct location e.g., cytosol or endosomal or lysosomal, secreted, membrane bound
- a first administration may employ viral delivery of cytoplasm targeted neoepitopes or polytope
- a second administration is typically at least a day, two days, four days, a week, or two weeks after the first administration and may employ viral delivery of endosomal or lysosomal targeted or secreted neoepitopes or polytope.
- the expression construct e.g., recombinant viral expression vector or plasmid
- suitable co-stimulatory molecules include CD80, CD86, CD30, CD40, CD30L, CD40L, ICOS-L, B7-H3, B7-H4, CD70, OX40L, 4-1BBL, while other stimulatory molecules with less defined (or understood) mechanism of action include GITR-L, TIM-3, TIM-4, CD48, CD58, TL1A, ICAM-1, LFA3, and members of the SLAM family.
- especially preferred molecules for coordinated expression with the cancer-associated sequences include CD80 (B7-1), CD86 (B7-2), CD54 (ICAM-1) and CD11 (LFA-1).
- cytokines or cytokine analogs may be expressed from the recombinant nucleic acid, and especially preferred cytokines and cytokine analogs include IL-2, IL-15, and IL-a5 superagonist (ALT-803).
- expression of the co-stimulatory molecules and/or cytokines will preferably be coordinated such that the neoepitopes or polytope are expressed contemporaneously with one or more co-stimulatory molecules and/or cytokines.
- co-stimulatory molecules and/or cytokines are produced from a single transcript (which may or may not include the sequence portion encoding the polytope), for example, using an internal ribosome entry site or 2A sequence, or from multiple transcripts.
- the viral vector may also include a sequence portion that encodes one or more peptide ligands that bind to a checkpoint receptor. Most typically, binding will inhibit or at least reduce signaling via the receptor, and particularly contemplated receptors include CTLA-4 (especially for CD8 + cells), PD-1 (especially for CD4 + cells), TIM1 receptor, 2B4, and CD160.
- suitable peptide binders can include antibody fragments and especially scFv, but also small molecule peptide ligands (e.g., isolated via RNA display or phage panning) that specifically bind to the receptors.
- peptide molecules will preferably be coordinated such that the neoepitopes or polytope are expressed contemporaneously with one or more of the peptide ligands.
- the peptide ligands are produced from a single transcript (which may or may not include the sequence portion encoding the polytope), for example, using an internal ribosome entry site or 2A sequence, or from multiple transcripts.
- contemplated expression constructs will preferably include a sequence portion that encodes one or more polytopes, wherein at least one, and more typically at least two, or all of the polytopes will include a trafficking signal that will result in preferential trafficking of the polytope to at least one, and more typically at least two different sub-cellular locations.
- the first polytope may be directed towards the cytoplasm (and may include an additional cleavable or non-cleavable ubiquitin) while the second polytope may be directed towards the endosomal or lysosomal compartment.
- the first polytope may be directed towards the endosomal or lysosomal compartment while the second polytope may be directed towards the cell membrane or be secreted.
- the encoded polytope will comprise at least two neoepitopes, optionally separated by a linker.
- contemplated expression constructs will also include a sequence portion that encodes one or more co-stimulatory molecules and/or cytokines, and may also include one or more inhibitory proteins that interfere with/down-regulate checkpoint inhibition.
- the expression construct will also include regulatory sequences operably coupled to the above sequence portions to drive contemporaneous expression of the polytope and the co-stimulatory molecules, cytokines, and/or inhibitory proteins. Suitable promoter elements are known in the art, and especially preferred promoters include the constitutive and inducible promoters discussed above.
- the expression construct is a viral expression construct (e.g., an adenovirus, and especially AdV with E1 and E2b deleted)
- the recombinant viruses may then be individually or in combination used as a therapeutic vaccine in a pharmaceutical composition, typically formulated as a sterile injectable composition with a virus titer of between 10 6 -10 13 virus particles, and more typically between 10 9 -10 12 virus particles per dosage unit.
- virus may be employed to infect patient (or other HLA matched) cells ex vivo and the so infected cells are then transfused to the patient.
- treatment of patients with the virus may be accompanied by allografted or autologous natural killer cells or T cells in a bare form or bearing chimeric antigen receptors expressing antibodies targeting neoepitope, neoepitopes, tumor associated antigens or the same payload as the virus.
- the natural killer cells which include the patient-derived NK-92 cell line, may also express CD16 and can be coupled with an antibody.
- additional therapeutic modalities may be employed which may be neoepitope based (e.g., synthetic antibodies against neoepitopes as described in WO 2016/172722), alone or in combination with autologous or allogenic NK cells, and especially haNK cells or taNK cells (e.g., both commercially available from NantKwest, 9920 Jefferson Blvd. Culver City, Calif. 90232).
- haNK or taNK cells are employed, it is particularly preferred that the haNK cell carries a recombinant antibody on the CD16 variant that binds to a neoepitope of the treated patient, and where taNK cells are employed it is preferred that the chimeric antigen receptor of the taNK cell binds to a neoepitope of the treated patient.
- the additional treatment modality may also be independent of neoepitopes, and especially preferred modalities include cell-based therapeutics such as activated NK cells (e.g., aNK cells, commercially available from NantKwest, 9920 Jefferson Blvd. Culver City, Calif. 90232), and non cell-based therapeutics such as chemotherapy and/or radiation.
- immune stimulatory cytokines and especially IL-2, IL15, and IL-21 may be administered, alone or in combination with one or more checkpoint inhibitors (e.g., ipilimumab, nivolumab, etc.).
- additional pharmaceutical intervention may include administration of one or more drugs that inhibit immune suppressive cells, and especially MDSCs Tregs, and M2 macrophages.
- suitable drugs include IL-8 or interferon- ⁇ inhibitors or antibodies binding IL-8 or interferon- ⁇ , as well as drugs that deactivate MDSCs (e.g., NO inhibitors, arginase inhibitors, ROS inhibitors), that block development of or differentiation of cells to MDSCs (e.g., IL-12, VEGF-inhibitors, bisphosphonates), or agents that are toxic to MDSCs (e.g., gemcitabine, cisplatin, 5-FU).
- drugs like cyclophosphamide, daclizumab, and anti-GITR or anti-OX40 antibodies may be used to inhibit Tregs.
- the chemotherapy and/or radiation for the patient may be done using a low-dose regimen, preferably in a metronomic fashion.
- a low-dose regimen preferably in a metronomic fashion.
- such treatment will use doses effective to affect at least one of protein expression, cell division, and cell cycle, preferably to induce apoptosis or at least to induce or increase the expression of stress-related genes (and particularly NKG2D ligands).
- such treatment will include low dose treatment using one or more chemotherapeutic agents.
- low dose treatments will be at exposures that are equal or less than 70%, equal or less than 50%, equal or less than 40%, equal or less than 30%, equal or less than 20%, equal or less than 10%, or equal or less than 5% of the LD 50 or IC 50 for the chemotherapeutic agent.
- such low-dose regimen may be performed in a metronomic manner as described, for example, in U.S. Pat. Nos. 7,758,891, 7,771,751, 7,780,984, 7,981,445, and 8,034,375.
- chemotherapeutic agents are deemed suitable.
- kinase inhibitors, receptor agonists and antagonists, anti-metabolic, cytostatic and cytotoxic drugs are all contemplated herein.
- particularly preferred agents include those identified to interfere or inhibit a component of a pathway that drives growth or development of the tumor.
- Suitable drugs can be identified using pathway analysis on omics data as described in, for example, WO 2011/139345 and WO 2013/062505.
- NK-cell mediated killing will be associated with release of intracellular tumor specific antigens, which is thought to further enhance the immune response.
- the inventors contemplate various methods of treatment of cancer in a patient in which a recombinant nucleic acid is administered to the patient (preferably in form of viral transfection in vivo) wherein the recombinant nucleic acid comprises a sequence portion that encodes one or more polytopes.
- a recombinant nucleic acid is administered to the patient (preferably in form of viral transfection in vivo) wherein the recombinant nucleic acid comprises a sequence portion that encodes one or more polytopes.
- at least one, and more typically at least two, or all of the polytopes include a trafficking signal that will result in preferential trafficking (e.g., at least 70%, more typically at least 80%, and most typically at least 90% of all expressed polytope is found in the targeted sub-cellular compartment) of the polytope to at least one, or at least two different sub-cellular locations.
- the first polytope may be directed towards the cytoplasm (and may include an additional cleavable or non-cleavable ubiquitin) while the second polytope may be directed towards the endosomal or lysosomal compartment.
- the first polytope may be directed towards the endosomal or lysosomal compartment while the second polytope may be directed towards the cell membrane or be secreted.
- the encoded polytope will comprise at least two neoepitopes, optionally separated by a linker.
- contemplated expression constructs will also include a sequence portion that encodes one or more co-stimulatory molecules and/or cytokines, and may also include one or more inhibitory proteins that interfere with/down-regulate checkpoint inhibition. Therefore, expression of the polytope may be accompanied by expression of the co-stimulatory molecules, cytokines, and/or inhibitory proteins.
- the expression construct will include regulatory sequences operably coupled to the above sequence portions to drive contemporaneous expression of the polytope and the co-stimulatory molecules, cytokines, and/or inhibitory proteins.
- contemplated compositions and methods may also be employed to trigger a CD8 + biased immune response (stimulation of cytotoxic T cells), to trigger a CD4 + biased immune response (producing Th1 and/or Th2 cytokine to stimulate B-cells, antibody production, and memory cells), an antibody biased immune response, and/or a stimulated immune response (at least partial reversal of checkpoint inhibition and/or increased activation of NK and T cell cytotoxicity).
- contemplated compositions and methods may be employed to support or increase such activity by targeting polytopes towards the cytoplasmic antigen presentation pathway to so increase MHC-I presentation and enhance a CD8 + biased immune response.
- contemplated compositions and methods may be employed to support or increase such activity by targeting polytopes towards the endosomal and/or lysosomal antigen presentation pathway to so increase MHC-II presentation, and with that enhance a CD4 + biased immune response.
- administering refers to both direct and indirect administration of the pharmaceutical composition or drug, wherein direct administration of the pharmaceutical composition or drug is typically performed by a health care professional (e.g., physician, nurse, etc.), and wherein indirect administration includes a step of providing or making available the pharmaceutical composition or drug to the health care professional for direct administration (e.g., via injection, infusion, oral delivery, topical delivery, etc.).
- a health care professional e.g., physician, nurse, etc.
- indirect administration includes a step of providing or making available the pharmaceutical composition or drug to the health care professional for direct administration (e.g., via injection, infusion, oral delivery, topical delivery, etc.).
- the recombinant virus is administered via subcutaneous or subdermal injection.
- administration may also be intravenous injection.
- antigen presenting cells may be isolated or grown from cells of the patient, infected in vitro, and then transfused to the patient. Therefore, it should be appreciated that contemplated systems and methods can be considered a complete drug discovery system (e.g., drug discovery, treatment protocol, validation, etc.) for highly personalized cancer treatment.
- drug discovery system e.g., drug discovery, treatment protocol, validation, etc.
- Neoepitope sequences were determined in silico by location-guided synchronous alignment of tumor and normal samples as, for example, disclosed in US 2012/0059670 and US 2012/0066001 using BAM files and BAM servers. Specifically, DNA analysis of the tumor was from the B16-F10 mouse melanoma line and matched normal was blood from C57bl/6 parental mouse DNA. The results were filtered for expression by RNA sequencing of this tumor cell line. Neoepitopes that were found expressed were further analyzed for binding affinity towards murine MHC-I (here: Kb) and MHC-II (here: I-Ab).
- Selected binders (with affinity of equal or less than 200 nM) were further analyzed after a further step of dbSNP filtering using positional permutations of all neoepitopes that were then processed through a weight matrix and neural network prediction to generate a score representing the likelihood of presence and/or strength of hydrophobic sequences or signal peptides.
- the best scoring arrangement (lowest likelihood of hydrophobic sequences or signal peptides) for the polytope (not shown) was used for further experiments.
- Neoepitopes were prioritized by detection in RNAseq or other quantitative system that yielded expression strength for a specific gene harboring the neoepitope mutation.
- Table 1 shows exemplary neoepitopes that were expressed as determined by RNAseq along with gene name and mutated amino acid and position of the mutated amino acid. The neoepitope listed with * was discarded after dbSNP filtering as that neoepitope occurred as variant Rs71257443 in 28% of the population.
- Neoepitope-a Neoepitope-b VIPR2 V73M GETVTMPCP LILRB3 T187N VGPVNPSHR* FCRL1 R286C GLGAQCSEA FAT4 S1613L RKLTTELTI PERRKLTTE PIEZO2 T2356M MDWVWMDTT VWMDTTLSL SIGLEC14 A292T GKTLNPSQT REGKTLNPS SIGLEC1 D1143N VRNATSYRC NVIVRNATS SLC4A11 Q678P FAMAQIPSL AQIPSLSLR
- Table 2 shows further examples of neoepitopes in which the position of the mutated amino acid was changed, and shows further alternate sequences for MHC-I presentation (9-mer) and MHC-II presentation (15-mer).
- the neoepitope sequence for MHC-II presentation was back-translated to the corresponding nucleic acid sequence, which is also shown in Table 2.
- Neoepitope-a Neoepitope-b Extended 15 mer Nucleotide Sequence SLC4A11 Q678P FAMAQIPSL AQIPSLSLR PFAMAQIPSLSLRAV CCCTTCGCCATGGCCC AGATCCCCAGCCTGA GCCTGAGGGCCGTG SIGLEC1 D1143N VRNATSYRC NVTVRNATS LPNVTVRNATSYRCG CTGCCCAACGTGACC GTGAGGAACGCCACC AGCTACAGGTGCGGC SIGLEC14 A292T GKTLNPSQT REGKTLNPS SWFREGKTLNPSQTS AGCTGGTTCAGGGAG GGCAAGACCCTGAAC CCCAGCCAGACCAGC PIEZO2 T2356M MDWVWMDTT VWMDTTLSL AVMDWVWMDTTLSLS GCCGTGATGGACTGG GTGTGGATGGACACC ACCCTGAGCCTGAGC FAT4 S1613L RKLTTELTI PERRKLTTE
- Murine B16-F10 melanoma (derived from C57/B16 mouse) was used tumors were screened in a tumor versus normal manner as described above, and expressed mutant epitopes were identified in the B16F10 melanoma cell line.
- Candidate neoepitopes were further filtered as described above using sequencing data analysis and binding analysis to murine MHC I (H2-Kb, H2-Dd) and MHC II (I-Ab).
- H2-Kb, H2-Dd murine MHC I
- I-Ab MHC II
- three polytope constructs included MHC I binding neoepitopes for MHC-I presentation and were therefore targeted to the cytoplasmic compartment. While one construct had an unmodified N-terminus, another construct had an N-terminal non-cleavable ubiquitin, and yet another construct had an N-terminal cleavable ubiquitin. Ubiquitination was used to target the proteasome in the cytosol. Three further polytope constructs included MHC I binding neoepitopes for MHC-II presentation and were therefore targeted to the lysosomal/endosomal compartments compartment.
- ubiquitin cleavable and non-cleavable
- CD1b leader peptide was used as an export leader peptide for trafficking the polypeptide out of the cytosol for all MHC-II directed sequences.
- LAMP1-TM/cytoplasmic tail was used as a lysosomal targeting sequence
- LAMP1-TM/CD1a tail was used as a recycling endosomes targeting sequence
- LAMP1-TM/CD1c tail was used as a sorting endosomes targeting domain.
- SIINFEKL peptide was used as an internal control for a MHC I restricted (Kb) peptide epitope
- Esat6 peptide was used as an internal control for a secreted protein for MHC II presentation
- FLAG-tag was used as an internal control epitope for detection of expression
- cMYC used as an internal control Tag for simple protein detection.
- FIG. 5A exemplarily depicts the polypeptide structure of such arrangement where the SIINFEKL motif is underlined, the Esat6 motif is in italics, and where the cMY motif is in bold type font.
- the nucleotide sequence for FIG. 5A is SEQ ID NO: 9, and the polypeptide sequence for FIG. 5A is SEQ ID NO: 12.
- FIG. 5B exemplarily depicts the polypeptide structure of such arrangement where the cleavable ubiquitin moiety is italics and underlined, the SIINFEKL motif is underlined, the Esat6 motif is in italics, and where the cMY motif is in bold type font.
- the nucleotide sequence for FIG. 5B is SEQ ID NO: 10
- the polypeptide sequence for FIG. 5B is SEQ ID NO: 13.
- FIG. 5C exemplarily depicts the polypeptide structure of such arrangement where the cleavable ubiquitin moiety is italics and underlined, the SIINFEKL motif is underlined, the Esat6 motif is in italics, and where the cMY motif is in bold type font.
- the nucleotide sequence for FIG. 5C is SEQ ID NO: 11, and the polypeptide sequence for FIG. 5C is SEQ ID NO: 14.
- FIG. 6A exemplarily depicts the polypeptide structure of such arrangement where the CD1b leader peptide moiety is bold, the Esat6 motif is in underlined, the Flag-tag motif is italics, and where the LAMP1TM/cytoplasmic tail is in bold/underline type font.
- the nucleotide sequence for FIG. 6A is SEQ ID NO: 15, and the polypeptide sequence for FIG. 6A is SEQ ID NO: 18.
- FIG. 6B exemplarily depicts the polypeptide structure of such arrangement where the CD1b leader peptide moiety is bold, the Esat6 motif is in underlined, the Flag-tag motif is italics, and where the LAMP1TM motif is in bold/underline type font, and the CD1a targeting motif is underline/italics.
- the nucleotide sequence for FIG. 6B is SEQ ID NO: 16, and the polypeptide sequence for FIG. 6B is SEQ ID NO: 19.
- FIG. 6C exemplarily depicts the polypeptide structure of such arrangement where the CD1b leader peptide moiety is bold, the Esat6 motif is in underlined, the Flag-tag motif is italics, and where the LAMP1TM motif is in bold/underline type font, and the CD1c targeting motif is underline/italics.
- the nucleotide sequence for FIG. 6C is SEQ ID NO: 17, and the polypeptide sequence for FIG. 6C is SEQ ID NO: 20.
- FIG. 7A exemplarily depicts the polypeptide structure of such arrangement where the CD1b leader peptide moiety is bold, the SIINFEKL and Esat6 motifs are underlined, the Flag-tag motif is italics, and where the LAMP1TM/cytoplasmic tail is in bold/underline type font.
- the nucleotide sequence for FIG. 7A is SEQ ID NO: 21, and the polypeptide sequence for FIG. 7A is SEQ ID NO: 24.
- FIG. 7B exemplarily depicts the polypeptide structure of such arrangement where the CD1b leader peptide moiety is bold, the SIINFEKL and Esat6 motifs are underlined, the Flag-tag motif is italics, where the LAMP1TM motif is in bold/underline type font, and where the CD1a tail is in bold/italics.
- the nucleotide sequence for FIG. 7B is SEQ ID NO: 22, and the polypeptide sequence for FIG. 7B is SEQ ID NO: 25.
- FIG. 7C exemplarily depicts the polypeptide structure of such arrangement where the CD1b leader peptide moiety is bold, the SIINFEKL and Esat6 motifs are underlined, the Flag-tag motif is italics, where the LAMP1TM motif is in bold/underline type font, and where the CD1c tail is in bold/italics.
- the nucleotide sequence for FIG. 7C is SEQ ID NO: 23, and the polypeptide sequence for FIG. 7C is SEQ ID NO: 26.
- FIG. 8 depicts an exemplary in vivo vaccination experiment where nine groups of C57bl/6 mice were immunized with nine distinct recombinant Ad5 viruses comprising the sequence arrangements substantially as described above Immunization followed a biweekly schedule of administration with distinct routes for separate groups of animals (subcutaneous and intravenous) as is schematically shown in FIG. 8 .
- Tumor challenge with B16-F10 melanoma cells was at day 42, followed by administration of an M2 macrophage suppressive drug (RP 182) and IL-15 superagonist (Alt-803).
- FIGS. 9A-9C depict exemplary results for subcutaneous administration
- FIGS. 10A-10C depict exemplary results for intravenous administration.
Abstract
Description
P(D g ,D t ,G g ,G t |α,r(=P(D g |G g)P(G g |r)P(D t |G g ,G t,α)P(G t |G g) (1)
P(D ↓g ,D ↓t ,G ↓g ,G ↓t ┤|α,r(=P(D ↓g ┤|G ↓g)P(G ↓g |r)P(D ↓t ┤|G ↓g ,G ↓t,α)P(G ↓t ┤|G ↓g) (1)
where r is the observed reference allele, α the fraction of normal contamination, and the tumor and germline genotypes are defined by Gt=(t1, t2) and Gg=(g1, g2) where t1, t2, g1, g2ε{A, T, C, G}. The tumor and germline sequence data are defined as a set of reads Dt={dt1, dt2, . . . , dtm} and Dg={dg1, dg2, . . . , dgm}, respectively, with the observed bases dti, dgiε{A, T, C, G}. All data used in the model must exceed user-defined base and mapping quality thresholds.
where n is the total number of germline reads at this position and nA, nG, nC, nT are the reads supporting each observed allele. The base probabilities, P(dgi|Gg), are assumed to be independent, coming from either of the two parental alleles represented by the genotype Gg, while also incorporating the approximate base error rate of the sequencer. The prior on the germline genotype is conditioned on the reference base as
P(G g |r=a)={μaa,μab,μbb},
where μaa is the probability that the position is homozygous reference, μab is heterozygous reference, and μbb is homozygous non-reference. At this time, the germline prior does not incorporate any information on known, inherited SNPs.
where m is the total number of germline reads at this position and mA, mG, mC, mT are the reads supporting each observed allele in the tumor dataset, and the probability of each tumor read is a mixture of base probabilities derived from both tumor and germline genotypes that is controlled by the fraction of normal contamination, α, as
P(d t i |G t ,G gα)=αP(d t i |G t)+(1−α)P(d t i |G g)
and the probability of the tumor genotype is defined by a simple mutation model from on the germline genotype
P(G t |G g)=max[P(t 1 |g 1)P(t 2 |g 2),P(t 1 |g 2)P(t 2 |g 1)],
where the probability of no mutation (for example, t1=g1) is maximal and the probability of transitions (that is, A→G, T→C) are four times more likely than transversions (that is, A→T, T→G). All model parameters, α, μaa, μab, μbb, and base probabilities, P(di|G), for the multinomial distributions are user-definable.
can be used to score the confidence in the pair of inferred genotypes. If the tumor and germline genotypes differ, the putative somatic mutation(s) will be reported along with its respective confidence.
TABLE 1 | |||||
Gene | Position | Neoepitope-a | Neoepitope-b | ||
VIPR2 | V73M | GETVTMPCP | |||
LILRB3 | T187N | VGPVNPSHR* | |||
FCRL1 | R286C | GLGAQCSEA | |||
FAT4 | S1613L | RKLTTELTI | PERRKLTTE | ||
PIEZO2 | T2356M | MDWVWMDTT | VWMDTTLSL | ||
SIGLEC14 | A292T | GKTLNPSQT | REGKTLNPS | ||
SIGLEC1 | D1143N | VRNATSYRC | NVIVRNATS | ||
SLC4A11 | Q678P | FAMAQIPSL | AQIPSLSLR | ||
TABLE 2 | |||||
Gene | Change | Neoepitope-a | Neoepitope-b | Extended 15 mer | Nucleotide Sequence |
SLC4A11 | Q678P | FAMAQIPSL | AQIPSLSLR | PFAMAQIPSLSLRAV | CCCTTCGCCATGGCCC |
AGATCCCCAGCCTGA | |||||
GCCTGAGGGCCGTG | |||||
SIGLEC1 | D1143N | VRNATSYRC | NVTVRNATS | LPNVTVRNATSYRCG | CTGCCCAACGTGACC |
GTGAGGAACGCCACC | |||||
AGCTACAGGTGCGGC | |||||
SIGLEC14 | A292T | GKTLNPSQT | REGKTLNPS | SWFREGKTLNPSQTS | AGCTGGTTCAGGGAG |
GGCAAGACCCTGAAC | |||||
CCCAGCCAGACCAGC | |||||
PIEZO2 | T2356M | MDWVWMDTT | VWMDTTLSL | AVMDWVWMDTTLSLS | GCCGTGATGGACTGG |
GTGTGGATGGACACC | |||||
ACCCTGAGCCTGAGC | |||||
FAT4 | S1613L | RKLTTELTI | PERRKLTTE | LGPERRKLTTELTII | CTGGGCCCCGAGAGG |
AGGAAGCTGACCACC | |||||
GAGCTGACCATCATC | |||||
FCRL1 | R286C | GLGAQCSEA | NNGLGAQCSEAVTLN | AACAACGGCCTGGGC | |
GCCCAGTGCAGCGAG | |||||
GCCGTGACCCTGAAC | |||||
VIPR2 | V73M | GETVTMPCP | NVGETVTMPCPKVFS | AACGTGGGCGAGACC | |
GTGACCATGCCCTGC | |||||
CCCAAGGTGTTCAGC | |||||
FLRT2 | R346W | EQVWGMAVR | CQGPEQVWGMAVREL | TGCCAGGGCCCCGAG | |
CAGGTGTGGGGCATG | |||||
GCCGTGAGGGAGCT | |||||
G | |||||
Claims (4)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/468,046 US11154597B2 (en) | 2016-03-24 | 2017-03-23 | Sequence arrangements and sequences for neoepitope presentation |
US16/874,104 US20200297830A1 (en) | 2016-03-24 | 2020-05-14 | Sequence arrangements and sequences for neoepitope presentation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662312974P | 2016-03-24 | 2016-03-24 | |
US201662313621P | 2016-03-25 | 2016-03-25 | |
US201662314366P | 2016-03-28 | 2016-03-28 | |
US15/468,046 US11154597B2 (en) | 2016-03-24 | 2017-03-23 | Sequence arrangements and sequences for neoepitope presentation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/874,104 Division US20200297830A1 (en) | 2016-03-24 | 2020-05-14 | Sequence arrangements and sequences for neoepitope presentation |
Publications (2)
Publication Number | Publication Date |
---|---|
US20170312351A1 US20170312351A1 (en) | 2017-11-02 |
US11154597B2 true US11154597B2 (en) | 2021-10-26 |
Family
ID=60157677
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/468,046 Active US11154597B2 (en) | 2016-03-24 | 2017-03-23 | Sequence arrangements and sequences for neoepitope presentation |
US16/874,104 Abandoned US20200297830A1 (en) | 2016-03-24 | 2020-05-14 | Sequence arrangements and sequences for neoepitope presentation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/874,104 Abandoned US20200297830A1 (en) | 2016-03-24 | 2020-05-14 | Sequence arrangements and sequences for neoepitope presentation |
Country Status (12)
Country | Link |
---|---|
US (2) | US11154597B2 (en) |
EP (1) | EP3475434A4 (en) |
JP (1) | JP2019513021A (en) |
KR (1) | KR20180117227A (en) |
CN (1) | CN109563521A (en) |
AU (1) | AU2017281126A1 (en) |
CA (1) | CA3018741A1 (en) |
IL (1) | IL261813A (en) |
MX (1) | MX2018011491A (en) |
SG (1) | SG11201807770RA (en) |
TW (1) | TW201742923A (en) |
WO (1) | WO2017222619A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200225229A1 (en) * | 2017-09-25 | 2020-07-16 | Nant Holdings Ip, Llc | Validation of Neoepitope Presentation |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180117227A (en) | 2016-03-24 | 2018-10-26 | 난트셀, 인크. | Sequences and sequence arrangements for neo-epitope presentation |
AU2017362730B2 (en) * | 2016-11-21 | 2021-04-08 | Nant Holdings Ip, Llc | Fractal combination therapy |
AU2018219862B2 (en) * | 2017-02-07 | 2020-09-17 | Nant Holding IP, LLC | Maximizing T-cell memory and compositions and methods therefor |
SG11201909882SA (en) * | 2017-04-24 | 2019-11-28 | Nantcell Inc | Targeted neoepitope vectors and methods therefor |
KR20200055136A (en) * | 2017-10-05 | 2020-05-20 | 난트셀, 인크. | Multivalent antigens that stimulate Th1 and Th2 (MULTIVALENT ANTIGENS STIMULATING TH1 AND TH2) |
US20200354730A1 (en) * | 2017-11-27 | 2020-11-12 | Nantcell, Inc. | Improved Yeast Polytope Vaccine Compositions And Methods |
EP3768698A4 (en) * | 2018-03-19 | 2022-03-30 | MultiVir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
US11267866B2 (en) | 2018-04-04 | 2022-03-08 | Nant Holdings Ip, Llc | Immunoglobulin complex comprising interleukin-15 |
TWI816603B (en) * | 2018-04-23 | 2023-09-21 | 美商南特細胞公司 | Neoepitope vaccine and immune stimulant combinations and methods |
US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
MX2020013621A (en) | 2018-06-19 | 2021-03-25 | Nantcell Inc | Hiv treatment compositions and methods. |
WO2020073045A1 (en) * | 2018-10-05 | 2020-04-09 | Nantcell, Inc. | Cd40 and cd40l combo in an adenovirus vaccine vehicle |
WO2020205100A1 (en) * | 2019-03-15 | 2020-10-08 | Nantcell, Inc. | Recombinant eril-15 nk cells |
CN111755073B (en) * | 2020-05-31 | 2022-11-15 | 复旦大学 | Transcriptome-based PD-1 therapy treatment effect prediction system |
WO2022086727A1 (en) * | 2020-10-19 | 2022-04-28 | Nantbio, Inc. | Arrayed peptide neoepitope generator |
Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000078806A1 (en) | 1999-06-18 | 2000-12-28 | Ludwig Institute For Cancer Research | Mage-a1 peptides presented by hla class ii molecules |
US20050095648A1 (en) | 2003-10-30 | 2005-05-05 | Mario Geysen | Method for designing linear epitopes and algorithm therefor and polypeptide epitopes |
US7179797B2 (en) | 2002-09-27 | 2007-02-20 | Wisconsin Alumni Research Foundation | Methods and compositions for treating prostate cancer using DNA vaccines |
US7473532B2 (en) | 2003-03-10 | 2009-01-06 | Expression Pathology, Inc. | Liquid tissue preparation from histopathologically processed biological samples, tissues and cells |
WO2009006479A2 (en) | 2007-07-02 | 2009-01-08 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
US7758891B2 (en) | 2005-02-18 | 2010-07-20 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US20100196411A1 (en) | 2006-02-02 | 2010-08-05 | Globelmmune, Inc. | Yeast-Based Vaccine for Inducing an Immune Response |
US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
US20110071214A1 (en) | 2008-05-14 | 2011-03-24 | Gregory John Allen | Methods and compositions for the treatment of cancer |
US7981445B2 (en) | 2005-08-31 | 2011-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
WO2011139345A2 (en) | 2010-04-29 | 2011-11-10 | The Regents Of The University Of California | Pathway recognition algorithm using data integration on genomic models (paradigm) |
US20110293637A1 (en) * | 2010-05-14 | 2011-12-01 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
US20120059670A1 (en) | 2010-05-25 | 2012-03-08 | John Zachary Sanborn | Bambam: parallel comparative analysis of high-throughput sequencing data |
US20120066001A1 (en) | 2010-05-25 | 2012-03-15 | John Zachary Sanborn | Bambam: Parallel comparative analysis of high-throughput sequencing data |
US20120107347A1 (en) | 2009-04-17 | 2012-05-03 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
WO2012159754A2 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
WO2013062505A1 (en) | 2011-10-26 | 2013-05-02 | The Regents Of The University Of California | Pathway recognition algorithm using data integration on genomic models (paradigm) |
US8445268B2 (en) | 2002-07-16 | 2013-05-21 | Viromed Co., Ltd. | Her-2/neu DNA vaccine having anti-cancer activity |
WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
WO2014082729A1 (en) | 2012-11-28 | 2014-06-05 | Biontech Ag | Individualized vaccines for cancer |
WO2014168874A2 (en) | 2013-04-07 | 2014-10-16 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
US20140363465A1 (en) | 2011-04-04 | 2014-12-11 | Beth Israel Deaconess Medical Center, Inc. | Mycobacterial vaccine vectors and methods of using the same |
WO2015095811A2 (en) | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
WO2016061087A1 (en) * | 2014-10-14 | 2016-04-21 | The Usa, As Represented By The Secretary, Dept. Of Health & Human Services | Peptide-based methods for treating pancreatic cancer |
WO2016172722A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
WO2016187508A2 (en) | 2015-05-20 | 2016-11-24 | The Broad Institute Inc. | Shared neoantigens |
WO2016191545A1 (en) | 2015-05-26 | 2016-12-01 | Advaxis, Inc. | Personalized delivery vector-based immunotherapy and uses thereof |
WO2016207859A1 (en) | 2015-06-24 | 2016-12-29 | Advaxis, Inc. | Manufacturing device and process for personalized delivery vector-based immunotherapy |
WO2017035392A1 (en) | 2015-08-25 | 2017-03-02 | Nantomics, Llc | Systems and methods for high-accuracy variant calling |
WO2017066256A2 (en) | 2015-10-12 | 2017-04-20 | Nantomics, Llc | Compositions and methods for viral cancer neoepitopes |
US20170224794A1 (en) | 2011-08-17 | 2017-08-10 | Globeimmune, Inc. | Yeast-muc1 immunotherapeutic compositions and uses thereof |
US20170246276A1 (en) | 2011-03-17 | 2017-08-31 | Globeimmune, Inc. | Yeast-brachyury immunotherapeutic compositions |
TW201742923A (en) | 2016-03-24 | 2017-12-16 | 河谷細胞股份有限公司 | Sequence arrangements and sequences for neoepitope presentation |
WO2018094309A2 (en) | 2016-11-21 | 2018-05-24 | Nant Holdings Ip, Llc | Fractal combination therapy |
WO2018100389A1 (en) | 2016-12-02 | 2018-06-07 | Nordic Semiconductor Asa | Voltage regulators |
WO2018200389A1 (en) | 2017-04-24 | 2018-11-01 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102657864B (en) * | 2012-04-28 | 2014-01-01 | 中国农业科学院兰州兽医研究所 | Immune adjuvant of foot-and-mouth disease vaccine and application of immune adjuvant |
-
2017
- 2017-03-23 KR KR1020187030362A patent/KR20180117227A/en not_active Application Discontinuation
- 2017-03-23 EP EP17815840.8A patent/EP3475434A4/en not_active Withdrawn
- 2017-03-23 US US15/468,046 patent/US11154597B2/en active Active
- 2017-03-23 WO PCT/US2017/023894 patent/WO2017222619A2/en active Application Filing
- 2017-03-23 SG SG11201807770RA patent/SG11201807770RA/en unknown
- 2017-03-23 CA CA3018741A patent/CA3018741A1/en not_active Abandoned
- 2017-03-23 AU AU2017281126A patent/AU2017281126A1/en not_active Abandoned
- 2017-03-23 MX MX2018011491A patent/MX2018011491A/en unknown
- 2017-03-23 CN CN201780017324.8A patent/CN109563521A/en active Pending
- 2017-03-23 JP JP2018550347A patent/JP2019513021A/en active Pending
- 2017-03-24 TW TW106110045A patent/TW201742923A/en unknown
-
2018
- 2018-09-16 IL IL261813A patent/IL261813A/en unknown
-
2020
- 2020-05-14 US US16/874,104 patent/US20200297830A1/en not_active Abandoned
Patent Citations (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000078806A1 (en) | 1999-06-18 | 2000-12-28 | Ludwig Institute For Cancer Research | Mage-a1 peptides presented by hla class ii molecules |
US8445268B2 (en) | 2002-07-16 | 2013-05-21 | Viromed Co., Ltd. | Her-2/neu DNA vaccine having anti-cancer activity |
US7179797B2 (en) | 2002-09-27 | 2007-02-20 | Wisconsin Alumni Research Foundation | Methods and compositions for treating prostate cancer using DNA vaccines |
US20070123487A1 (en) | 2002-09-27 | 2007-05-31 | Wisconsin Alumni Research Foundation | Methods and Compositions for Treating Prostate Cancer Using DNA Vaccines |
US7473532B2 (en) | 2003-03-10 | 2009-01-06 | Expression Pathology, Inc. | Liquid tissue preparation from histopathologically processed biological samples, tissues and cells |
US20050095648A1 (en) | 2003-10-30 | 2005-05-05 | Mario Geysen | Method for designing linear epitopes and algorithm therefor and polypeptide epitopes |
US7758891B2 (en) | 2005-02-18 | 2010-07-20 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US7780984B2 (en) | 2005-02-18 | 2010-08-24 | Abraxis Bioscience, Llc | Methods and compositions for treating proliferative diseases |
US8034375B2 (en) | 2005-02-18 | 2011-10-11 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
US7981445B2 (en) | 2005-08-31 | 2011-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
US20100196411A1 (en) | 2006-02-02 | 2010-08-05 | Globelmmune, Inc. | Yeast-Based Vaccine for Inducing an Immune Response |
WO2009006479A2 (en) | 2007-07-02 | 2009-01-08 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
US20110071214A1 (en) | 2008-05-14 | 2011-03-24 | Gregory John Allen | Methods and compositions for the treatment of cancer |
US20120107347A1 (en) | 2009-04-17 | 2012-05-03 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
WO2011139345A2 (en) | 2010-04-29 | 2011-11-10 | The Regents Of The University Of California | Pathway recognition algorithm using data integration on genomic models (paradigm) |
US20110293637A1 (en) * | 2010-05-14 | 2011-12-01 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
US20120059670A1 (en) | 2010-05-25 | 2012-03-08 | John Zachary Sanborn | Bambam: parallel comparative analysis of high-throughput sequencing data |
US20120066001A1 (en) | 2010-05-25 | 2012-03-15 | John Zachary Sanborn | Bambam: Parallel comparative analysis of high-throughput sequencing data |
US20170246276A1 (en) | 2011-03-17 | 2017-08-31 | Globeimmune, Inc. | Yeast-brachyury immunotherapeutic compositions |
US20140363465A1 (en) | 2011-04-04 | 2014-12-11 | Beth Israel Deaconess Medical Center, Inc. | Mycobacterial vaccine vectors and methods of using the same |
US20140178438A1 (en) | 2011-05-24 | 2014-06-26 | Ugur Sahin | Individualized vaccines for cancer |
WO2012159754A2 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
US20170224794A1 (en) | 2011-08-17 | 2017-08-10 | Globeimmune, Inc. | Yeast-muc1 immunotherapeutic compositions and uses thereof |
WO2013062505A1 (en) | 2011-10-26 | 2013-05-02 | The Regents Of The University Of California | Pathway recognition algorithm using data integration on genomic models (paradigm) |
WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
WO2014082729A1 (en) | 2012-11-28 | 2014-06-05 | Biontech Ag | Individualized vaccines for cancer |
JP2016501870A (en) | 2012-11-28 | 2016-01-21 | バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーBiontech Rna Pharmaceuticals Gmbh | Personalized vaccine for cancer |
WO2014168874A2 (en) | 2013-04-07 | 2014-10-16 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
WO2015095811A2 (en) | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
KR20160101073A (en) | 2013-12-20 | 2016-08-24 | 더 브로드 인스티튜트, 인코퍼레이티드 | Combination therapy with neoantigen vaccine |
US20160339090A1 (en) * | 2013-12-20 | 2016-11-24 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
WO2016061087A1 (en) * | 2014-10-14 | 2016-04-21 | The Usa, As Represented By The Secretary, Dept. Of Health & Human Services | Peptide-based methods for treating pancreatic cancer |
WO2016172722A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
WO2016187508A2 (en) | 2015-05-20 | 2016-11-24 | The Broad Institute Inc. | Shared neoantigens |
WO2016191545A1 (en) | 2015-05-26 | 2016-12-01 | Advaxis, Inc. | Personalized delivery vector-based immunotherapy and uses thereof |
WO2016207859A1 (en) | 2015-06-24 | 2016-12-29 | Advaxis, Inc. | Manufacturing device and process for personalized delivery vector-based immunotherapy |
WO2017035392A1 (en) | 2015-08-25 | 2017-03-02 | Nantomics, Llc | Systems and methods for high-accuracy variant calling |
WO2017066256A2 (en) | 2015-10-12 | 2017-04-20 | Nantomics, Llc | Compositions and methods for viral cancer neoepitopes |
TW201742923A (en) | 2016-03-24 | 2017-12-16 | 河谷細胞股份有限公司 | Sequence arrangements and sequences for neoepitope presentation |
WO2017222619A2 (en) | 2016-03-24 | 2017-12-28 | Nantcell, Inc. | Sequence arrangements and sequences for neoepitope presentation |
CA3018741A1 (en) | 2016-03-24 | 2017-12-28 | Nantcell, Inc. | Sequence arrangements and sequences for neoepitope presentation |
KR20180117227A (en) | 2016-03-24 | 2018-10-26 | 난트셀, 인크. | Sequences and sequence arrangements for neo-epitope presentation |
CN109563521A (en) | 2016-03-24 | 2019-04-02 | 河谷细胞有限公司 | Series arrangement and sequence for new Epitope presentation |
JP2019513021A (en) | 2016-03-24 | 2019-05-23 | ナントセル,インコーポレイテッド | Arrangement and sequence of sequences for neoepitope presentation |
WO2018094309A2 (en) | 2016-11-21 | 2018-05-24 | Nant Holdings Ip, Llc | Fractal combination therapy |
WO2018100389A1 (en) | 2016-12-02 | 2018-06-07 | Nordic Semiconductor Asa | Voltage regulators |
WO2018200389A1 (en) | 2017-04-24 | 2018-11-01 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
KR20190137165A (en) | 2017-04-24 | 2019-12-10 | 난트셀, 인크. | TARGETED NEOEPITOPE VECTORS AND METHODS THEREFOR |
CN110662841A (en) | 2017-04-24 | 2020-01-07 | 河谷细胞有限公司 | Targeted neoepitope vectors and methods thereof |
US20200054730A1 (en) | 2017-04-24 | 2020-02-20 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
Non-Patent Citations (73)
Title |
---|
Amalfitano et al., "Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted", Journal of Virology, 1998, vol. 72, No. 2, pp. 926-933. |
Amalfitano et al., "Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted", Journal of Virology, Feb. 1998, vol. 72, No. 2, pp. 926-933 (Cited from Specification). |
Andarini et al., "Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts", Cancer Research, 2004, vol. 64, 3281-3287. |
Boyer et al., "Vaccination of Seronegative Volunteers with a Human Immunodeficiency Virus Type 1 env/rev DNA Vaccine Induces Antigen-Specific Proliferation and Lymphocyte Production of β-Chemokines", The Journal of Infectious Diseases, Feb. 2000, vol. 181, pp. 476-483. |
Brennick et al Immunotherapy, 9, 361-371 (Year: 2017). * |
Briken et al., "Intracellular trafficking pathway of newly synthesized CD1b molecules", The EMBO Journal, 2002, vol. 21, No. 4, pp. 825-834. |
Charoentong et al. Cancer Immunol. Immunother. 61:1885-1903 (Year: 2012). * |
Chu et al., "Indigenous enteric eosinophils control DCs to initiate a primary Th2 immune response in vivo" The Journal of Experimental Medicine 2014, vol. 211, pp. 1657-1672. |
Communication pursuant to Rules 70(2) and 70a(2) EPC received for European Patent Application Serial No. 17815840.8 dated Jul. 14, 2020, 1 page. |
Cong et al., "Cytoskeletal protein PSTPIP1 directs the PEST-type protein tyrosine phosphatase to the c-Abl kinase to mediate Abl dephosphorylation", Molecular Cell, Dec. 2000, vol. 6, pp. 1413-1423. |
Davoli et al., "Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome", Cell, Nov. 7, 2013, vol. 155, No. 4, pp. 948-962 (Cited from Specification). |
Decision of Refusal received for Japanese Patent Application Serial No. 2018550347 dated Aug. 25, 2020, 2 pages (Including English Translation). |
Dees et al., "MuSiC: Identifying mutational significance in cancer genomes", Genome Research, Jul. 3, 2012, vol. 22, No. 8, pp. 1589-1598 (Cited from Specification). |
Examination Report No. 1 received for Australian Patent Application Serial No. 2018258119 dated Mar. 1, 2021, 4 pages. |
Extended European search report received for European Patent Application Serial No. 17815840.8 dated Jun. 25, 2020, 14 pages. |
Extended European search report received for European Patent Application Serial No. 18791753.9 dated Jan. 28, 2021, 11 pages. |
Fejer et al., "Adenovirus-Triggered Innate Signalling Pathways", European Journal of Microbiology and Immunology, 2011, vol. 1, No. 4, pp. 279-288. |
Feltquate et al., "Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization", The journal of Immunology, 1997, vol. 158, No. 5, pp. 2278-2284. |
Final Office Action received for U.S. Appl. No. 16/874,104 dated Apr. 4, 2021, 109 pages. |
First Examiner's Report received for Canadian Patent Application Serial No. 3018741 dated Oct. 17, 2019, 4 pages. |
First Office Action received for Japanese Patent Application Serial No. 2018-550347 dated Jan. 21, 2020, 07 pages (Including English Translation). |
First Office Action received for Korean Patent Application Serial No. 10-2018-7030362 dated Aug. 30, 2019, 11 pages (Including English Translation). |
Fritsch et al., "HLA-binding properties of tumor neoepitopes in humans", Cancer Immunology Research, Jun. 2014, vol. 2, No. 6, pp. 522-529. |
Fukuda et al., "Cloning of cDNAs Encoding Human Lysosomal Membrane Glycoproteins, h-lamp-1 and h-lamp-2", The Journal of Biological Chemistry, Dec. 15, 1988, vol. 263, No. 35, pp. 18920-18928. |
Gonzalez-Perez et al., "Functional impact bias reveals cancer drivers", Nucleic Acids Research, Aug. 16, 2012, vol. 40, No. 21, p. 1-10 (Cited from Specification). |
Goya et al., SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors, Bioinformatics, 2010, vol. 26, No. 6, pp. 730-736 (Cited from Specification). |
Grant of Patent received for Korean Patent Application Serial No. KR10-2019-7034742 dated Sep. 7, 2021, 2 pages (Including English Translation). |
Habib-Agahi., "Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells", International Immunology, 2007, vol. 19, No. 2, pp. 1383-1394. |
Heijne G.V, "A new method for predicting signal sequence cleavage sites", Nucleic Acids Research, Jun. 11, 1986, vol. 14, No. 11, pp. 4683-4690 (Cited from Specification). |
Hodi et al., "Improved survival with ipilimumab in patients with metastatic melanoma", The New England Journal of Medicine, 2010, vol. 363, No. 8, pp. 711-723. |
International Preliminary Report on Patentability received for PCT Application Serial No. PCT/US2017/023894 dated Feb. 26, 2019, 08 pages. |
International Preliminary Report received in PCT Application Serial No. PCT/US2018/028889, dated Aug. 28, 2019, 9 pages. |
International Search Report and Written Opinion received for PCT Application Serial No. PCT/US2017/023894 dated Feb. 18, 2019, 13 pages. |
International Search Report and Written Opinion received for PCT Application Serial No. PCT/US2018028889 dated Aug. 14, 2018, 22 pages. |
International Search Report and Written Opinion received for Singapore Patent Application Serial No. 11201807770R dated Jan. 22, 2020, 13 pages. |
Jones et al., "A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes", PLOS Pathogens, 2016, vol. 12, No. 4, e1005545, pp. 1-25. |
Kall et al., "A Combined Transmembrane Topology and Signal Peptide Prediction Method", Journal of Molecular Biology, 2004, vol. 338, No. 5, pp. 1027-1036(Cited from Specification). |
Kim et al Molecular Therapy 16 No. 3, 599-606 (Year: 2008). * |
Kouchakzadeh et al., "Efficient Delivery of Therapeutic Agents by Using Targeted Albumin Nanoparticles", Advances in Protein Chemistry and Structural Biology, 2015, vol. 98, 23 pages (Cited from Specification). |
Kouchakzadeh Hasan et al., "Efficient Delivery of Therapeutic Agents by Using Targeted Albumin Nanoparticles", Elsevier Inc, 2015, vol. 98, pp. 121-143. |
Kreiter et al The Journal of Immunology, 180: 309-318 (Year: 2008). * |
Lawrence et al., "Discovery and saturation analysis of cancer genes across 21 tumour types", Nature, Jan. 23, 2014, vol. 505, No. 7484, pp. 495-501 (Cited from Specification). |
Li et al., "Mapping short DNA sequencing reads and calling variants using mapping quality scores", Genome Research, 2008, vol. 18, No. 11, pp. 1851-1858 (Cited from Specification). |
Lundegaard et al., "NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11", Nucleic Acids Research, May 7, 2008, vol. 36, Web Server issue, pp. W509-W512 (Cited from Specification). |
Mateo et al., "An HLA-A2 polyepitope vaccine for melanoma immunotherapy", The Journal of Immunology, Oct. 1, 1999, vol. 163, No. 7, pp. 4058-4063. |
McCluskie Mol. Med. 5:287-300 (Year: 1999). * |
Mincheff et al., "Naked DNA and Adenoviral Immunizations for Immunotherapy of Prostate Cancer: A Phase I/II Clinical Trial", European Urology, 2000, vol. 38, 2 pages. |
Mincheff et al., "Naked DNA and Adenoviral Immunizations for Immunotherapy of Prostate Cancer: A Phase I/II Clinical Trial", European Urology, 2000, vol. 38, pp. 208-217. |
Mularoni et al., "OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations", Genome Biology, 2016, vol. 17, No. 1, p. 1-13 (Cited from Specification). |
Niazi et al Immunology, 122, 522-531 (Year: 2007). * |
Non Final Office Action received for U.S. Appl. No. 16/874,104 dated Aug. 19, 2021, 51 pages. |
Non Final Office Action received for U.S. Appl. No. 16/874,104 dated Dec. 2, 2020, 116 pages. |
Notice of acceptance received for Australian Patent Application Serial No. 2018258119 dated Mar. 18, 2021, 3 pages. |
Notice of Final Rejection received for Korean Patent Application Serial No. 10-2018-7030362 dated Jul. 6, 2020, 2 pages (Including English Translation). |
Notice of Final Rejection received for Korean Patent Application Serial No. 10-2019-7034742 dated Jul. 8, 2021, 8 pages (Including English Translation). |
Notice of Grounds for Rejection received for Korean Patent Application Serial No. 1020187030362 dated Feb. 27, 2020, 14 pages (Including English Translation). |
Notice of Reasons for Refusal received for Japanese Patent Application Serial No. 2019557605 dated Feb. 2, 2021, 7 pages (Including English Translation). |
Notification of Reason for Refusal received for Korean Patent Application Serial No. 10-2019-7034742 dated Jan. 5, 2021, 13 pages (Including English Translation). |
Noting of loss of rights pursuant to Rule 112(1) EPC received for European Patent Application Serial No. 17815840.8 dated Feb. 18, 2021, 2 pages. |
Office Action received for Canadian patent Application Serial No. 3061240 dated Dec. 9, 2020, 6 pages. |
Office Action received for Taiwanese Patent Application Serial No. 106110045 dated Jan. 4, 2021, 4 pages (Including English Translation). |
Office Action received for Taiwanese Patent Application Serial No. 106110045 dated Sep. 14, 2020, 16 pages (Including English Translation). |
Partial European Search Report received for European Patent Application Serial No. 17815840.8 dated Mar. 2, 2020, 16 pages. |
Reimand et al., "Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers", Molecular Systems Biology, 2013, vol. 9, No. 637, p. 1-18 (Cited from Specification). |
Scheerlinck et al Vaccine. 21;19(17-19):2647-56 (Year: 2001). * |
Schroeder et al., "OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action", Bioinformatics, 2014, vol. 30, No. 17, pp. i549-i555 (Cited from Specification). |
Sloan et al., "MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells", Cancer Gene Therapy, 2002, vol. 9, No. 11, pp. 946-950. |
Sorber (NIH Medical Research Scholars Program, 2014-2015 Scholars and Abstracts, pp. 1-48 Abstract p. 39). (Year: 2014). |
Sykulev et al., "Evidence that a Single Peptide-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response", Immunity, Jun. 1, 1996, vol. 4, No. 6, pp. 565-571 (Cited from Specification). |
Tamborero et al., "OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes", Bioinformatics, 2013, vol. 29, No. 18, pp. 2238-2244 (Cited from Specification). |
Xu et al., "Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interieukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma", Cancer Research, 2013, vol. 73, No. 10, pp. 3075-3086. |
Zhang et al., "An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells", PNAS, Dec. 9, 2003, vol. 1 00, No. 25, p. 1-25. |
Zhang et al., "Machine learning competition in immunology—Prediction of HLA class I binding peptides", Journal of Immunological Methods, 2011, vol. 374, No. (1-2), p. 1-4 (Cited from Specification). |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200225229A1 (en) * | 2017-09-25 | 2020-07-16 | Nant Holdings Ip, Llc | Validation of Neoepitope Presentation |
Also Published As
Publication number | Publication date |
---|---|
WO2017222619A3 (en) | 2019-03-28 |
JP2019513021A (en) | 2019-05-23 |
CN109563521A (en) | 2019-04-02 |
WO2017222619A2 (en) | 2017-12-28 |
KR20180117227A (en) | 2018-10-26 |
CA3018741A1 (en) | 2017-12-28 |
US20200297830A1 (en) | 2020-09-24 |
MX2018011491A (en) | 2019-08-01 |
SG11201807770RA (en) | 2018-10-30 |
US20170312351A1 (en) | 2017-11-02 |
TW201742923A (en) | 2017-12-16 |
EP3475434A4 (en) | 2020-07-29 |
IL261813A (en) | 2018-10-31 |
EP3475434A2 (en) | 2019-05-01 |
AU2017281126A1 (en) | 2018-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11154597B2 (en) | Sequence arrangements and sequences for neoepitope presentation | |
AU2019280006B2 (en) | Improved compositions and methods for viral delivery of neoepitopes and uses thereof | |
AU2016339022B2 (en) | Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor | |
US20240016914A1 (en) | Targeted Neoepitope Vectors And Methods Therefor | |
US20210386844A1 (en) | Subcutaneous Delivery of Adenovirus with Dual Targeting | |
US20210369825A1 (en) | Cd40 and cd40l combo in an adv vaccine vehicle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NANTCELL, INC., CALIFORNIA Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:RABIZADEH, SHAHROOZ;REEL/FRAME:042347/0927 Effective date: 20170324 Owner name: NANT HOLDINGS IP, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOON-SHIONG, PATRICK;REEL/FRAME:042347/0863 Effective date: 20170405 Owner name: NANTCELL, INC., CALIFORNIA Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:NIAZI, KAYVAN;REEL/FRAME:042347/0866 Effective date: 20170405 Owner name: NANT HOLDINGS IP, LLC, CALIFORNIA Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:SOON-SHIONG, PATRICK;REEL/FRAME:042347/0924 Effective date: 20170405 |
|
AS | Assignment |
Owner name: NANTOMICS, LLC, CALIFORNIA Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:NGUYEN, ANDREW;REEL/FRAME:043538/0957 Effective date: 20170825 |
|
AS | Assignment |
Owner name: NANTOMICS, LLC, CALIFORNIA Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:BENZ, STEPHEN CHARLES;REEL/FRAME:043548/0792 Effective date: 20170828 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING TC RESP, ISSUE FEE PAYMENT VERIFIED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: INFINITY SA LLC, AS PURCHASER AGENT, NEW YORK Free format text: SECURITY INTEREST;ASSIGNORS:IMMUNITYBIO, INC.;NANTCELL, INC.;RECEPTOME, INC.;AND OTHERS;REEL/FRAME:066179/0074 Effective date: 20231229 |